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A B S T R A C T
Background
Diseases caused by Streptococcus pneumoniae (S. pneumoniae) continue to cause substantial morbidity and mortality globally. Whilst
pneumococcal polysaccharide vaccines (PPVs) have the potential to prevent disease and death, the degree of protection afforded against
various clinical endpoints and within different populations is uncertain.
Objectives
To assess the efficacy and effectiveness of PPVs in preventing pneumococcal disease or death in adults. We did not assess adverse events.
Search methods
We searched CENTRAL 2012, Issue 6, MEDLINE (January 1966 to June Week 2, 2012) and EMBASE (1974 to June 2012).
Selection criteria
We considered randomised controlled trials (RCTs) in adults, provided the study outcome met the definition of the outcome considered
in the review. We also considered non-RCTs in adults, where the study assessed PPV effectiveness against culture-confirmed invasive
pneumococcal disease (IPD), provided the study controlled for important confounding factors.
Data collection and analysis
Two review authors assessed trial quality of RCTs and three review authors extracted the data. We estimated odds ratios (ORs) and
95% confidence intervals (CIs) using a random-effects model. Two review authors assessed study quality and extracted data for non-
RCTs. We calculated ORs and 95% CIs using a random-effects model following the conversion of each study outcome to a log OR
and standard error (SE).
Main results
Twenty-five studies met our inclusion criteria (18 RCTs involving 64,852 participants and seven non-RCTs involving 62,294 partici-
pants). Meta-analysis of the RCTs found strong evidence of PPV efficacy against IPD with no statistical heterogeneity (OR 0.26, 95%
CI 0.14 to 0.45; random-effects model, I2 statistic = 0%). There was efficacy against all-cause pneumonia in low-income (OR 0.54,
95% CI 0.43 to 0.67, I2 statistic = 19%) but not high-income countries in either the general population (OR 0.71, 95% CI 0.45 to
1.12, I2 statistic = 93%) or in adults with chronic illness (OR 0.93, 95% CI 0.73 to 1.19, I2 statistic = 10%). PPV was not associated
with substantial reductions in all-cause mortality (OR 0.90, 95% CI 0.74 to 1.09; random-effects model, I2 statistic = 69%). Vaccine
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efficacy against primary outcomes appeared poorer in adults with chronic illness. Non-RCTs provided evidence for protection against
IPD in populations for whom the vaccine is currently utilised (OR 0.48, 95% CI 0.37 to 0.61; random-effects model, I2 statistic =
31%). This review did not consider adverse events as it was outside the scope of the review.
Authors’ conclusions
This meta-analysis provides evidence supporting the recommendation for PPV to prevent IPD in adults. The evidence from RCTs is
less clear with respect to adults with chronic illness. This might be because of lack of effect or lack of power in the studies. The meta-
analysis does not provide evidence to support the routine use of PPV to prevent all-cause pneumonia or mortality.
P L A I N L A N G U A G E S U M M A R Y
Vaccination for preventing pneumococcal infection in adults
Streptococcus pneumoniae (S. pneumoniae) is responsible for a considerable burden of illness and death in adults worldwide, usually
from pneumonia and less often from invasive pneumococcal disease. Vaccination (using pneumococcal polysaccharide vaccines) might
reduce such illness and death. This updated review included 18 randomised controlled trials involving 64,901 participants and
seven non-randomised controlled trials involving 62,294 participants (the latter contributing outcomes for culture-confirmed invasive
pneumococcal disease only).
We found consistently strong evidence that the vaccine is effective in preventing the rarer outcome of invasive pneumococcal disease.
Evidence from the included studies indicates vaccination might not afford as much protection in adults with chronic illness as it does
for healthy adults. The available evidence does not demonstrate that pneumococcal polysaccharide vaccines prevent pneumonia (of all
causes) or mortality in adults. This review did not consider adverse events as it was outside the scope of the study.
B A C K G R O U N D
Description of the condition
Pneumococcal pneumonia and other diseases caused by Streptococ-
cus pneumoniae (S. pneumoniae) continue to cause substantial mor-
bidity andmortality throughout the world. Pneumonia is themost
common presentation of pneumococcal disease in adults. Bacter-
aemic pneumonia is the most common cause of invasive pneu-
mococcal disease (IPD), accounting for 90% of all cases (Fedson
2004). Mortality associated with invasive pneumococcal pneumo-
nia in adults has remained unchanged at about 20% over the past
60 years (Austrian 1964; Harboe 2009; Rello 2010).
Studies on the epidemiology of pneumococcal disease in high-
income countries indicate that the highest incidence of disease is
among the very young and the elderly (Butler 2004). However,
some populations experience an increased disease incidence at a
young adult age, such as Australian Indigenous persons aged 15 to
49 years, where the incidence of IPD is 10 times greater than the
rate in non-Indigenous population (Menzies 2004). The epidemi-
ology of pneumococcal disease in adults in low-income countries
has not been well described but the global burden of pneumonia
in adults is likely to be significantly underestimated (Mulholland
1999).
The continuing burden of pneumococcal disease is worsened by
increasing numbers of people with chronic disease or HIV infec-
tion and an ageing population in many high-income countries.
Antibiotic resistance continues to present a major threat to the
successful treatment of infections (Reacher 2000; Tomasz 1995).
In low-income countries large numbers of people lack access to
basic curative health care but might be reached by vaccination
programmes.
Several population groups are at elevated risk of pneumococcal
disease. Individuals with chronic disease (chronic lung disease,
sickle cell anaemia, asplenic patients) or other conditions associ-
ated with a compromised immune status have been shown to have
increased susceptibility to disease (Butler 2004). Other popula-
tions are at elevated risk due to environmental conditions, includ-
ing overcrowding, exposure to air pollutants such as smoke and
differences in serotype distribution (Butler 2004). It is unknown
whether the higher rates of IPD in older adults in high-income
countries is due to changes in the immune system, or the presence
of underlying disease. A recent Cochrane Review (Walters 2010)
2Vaccines for preventing pneumococcal infection in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
failed to show any protective efficacy of pneumococcal polysac-
charide vaccine (PPV) in patients with chronic obstructive pul-
monary disease, with seven trials included in the meta-analysis.
Description of the intervention
The search for a vaccine to protect against pneumococcal dis-
ease began with the first whole cell vaccine trial involving min-
ers in South Africa, in 1911 (Wright 1914). Following MacLeod’s
trial of a four-valent PPV on military recruits in 1944 to 1945
(MacLeod 1945), a six-valent PPV became available for a short
period, from 1946 to 1948 but was withdrawn following the in-
creased use of penicillin. The continued high burden and severity
of pneumococcal disease (despite the availability of antibiotics),
has led to renewed calls for vaccine development and use. Trials of
a six-valent PPV and a 13-valent PPV among South African gold
miners (Austrian 1976a) and a 14-valent PPV trial in Papua New
Guinean highlanders (Riley 1977), showed strong vaccine efficacy
against bacteraemic pneumonia. Where specified, these vaccines
contained 50 µG of each purified capsular polysaccharide. A 14-
valent PPV was licensed for use in the United States in 1977; in
1983 this was replaced by a 23-valent formulation, containing a
reduced 25 µG of each purified capsular polysaccharide, without
additional pre-licensure trials.
Nasopharyngeal pneumococcal colonisation plays an essential role
in the disease process. It is also recognised for its value in measur-
ing the potential benefits (or harms) of vaccination, including di-
rect effects on immunised individuals as well as indirect effects via
transmission between immunised and non-immunised individu-
als (herd effects). Changes in nasopharyngeal carriage in response
to pneumococcal conjugate vaccine (PCV) indicate a reduction in
carriage of vaccine serotypes in immunised individuals and, im-
portantly, a reduction in transmission to the non-immunised pop-
ulation. These herd effects are reflected in significant reductions
in rates of vaccine serotype invasive disease in the non-immunised
population (Whitney 2003). Conversely, replacement of vaccine
serotypes by carriage with serotypes not included in the vaccine
has been documented in both vaccinated and non-vaccinated in-
dividuals and has been variously reflected in rates of disease caused
by non-vaccine serotypes (Whitney 2003). In contrast to PCV,
herd effects of PPV have been poorly described, possibly because
the required threshold of vaccine coverage has not been achieved
in any studied population. There is a general consensus that PPV
does not confer protection against carriage (Makela 2004). In view
of the herd effects of PCV and in order to establish any evidence
for this assumed consensus, we added this additional outcome to
themeta-analysis when the protocol was amended for the previous
Cochrane Review (Moberley 2008).
How the intervention might work
Prior to the discovery of antibiotics, anti-sera to the polysaccharide
capsule was the most effective therapy for pneumococcal pneu-
monia, reducing mortality to 5% if administered within 24 hours
of the onset of symptoms (Casadevall 1994). The discovery of dif-
ferences in the structure of the polysaccharide capsule (serotypes)
and the need for anti-pneumococcal sera to be specific to each cap-
sular serotype, led to the belief that the most effective protection
against pneumococcal disease was opsonisation of the polysaccha-
ride coat with antibody. There are over 90 different serotypes of S.
pneumoniae; some are highly invasive, whereas others rarely cause
disease. In addition, there is variation in the serotype distribution
between age groups and across different geographical populations
(Fedson 2004).
Although there is no known immunological correlate of protection
against pneumococcal disease, several groups (with some chronic
illnesses, immunocompromised conditions and older adults) have
been identified as either poor responders to all or some of the
pneumococcal polysaccharide serotypes contained within the vac-
cine. Differences in the immunogenicity of 23-valent PPV have
also been noted across population groups (McMahon 1993) with
genetic factors also thought to influence antibody responses to the
pneumococcal capsular polysaccharides (Pandey 2000).
Why it is important to do this review
The 23-valent PPV has been utilised internationally to varying
extents but mainly limited to older adults and adults with medical
risk factors for IPD in high-income countries (Fedson 1998). This
review updates the previous Cochrane Review (Moberley 2008)
and addresses whether PPV is effective in all adult populations or
whether only some groups benefit.
O B J E C T I V E S
To assess the efficacy and effectiveness of PPVs in preventing pneu-
mococcal disease or death in adults. We did not assess adverse
events. Specifically, the primary aims of this review were to assess:
• the efficacy and effectiveness of PPV in preventing IPD;
• the efficacy of PPV against all-cause pneumonia; and
• the efficacy against all-cause mortality in adults.
Secondary aims of this review were to assess vaccine efficacy in
preventing:
• definitive and presumptive pneumococcal pneumonia;
• death due to pneumonia or pneumococcal disease; and
• pneumococcal nasopharyngeal colonisation.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Prospective, randomised controlled trials (RCTs) or quasi-
RCTs that compared PPV with placebo, control vaccines or no
intervention.
2. Non-RCTs that assessed pneumococcal vaccine
effectiveness against sterile site, culture confirmed IPD where the
trial design allowed for the control of important confounding
factors (case-control and cohort studies). We excluded studies
reporting outcomes according to International Classification of
Diseases codes.
Types of participants
Adults of either sex, aged 16 years and above. We excluded studies
limited to HIV-positive participants as these are the subject of a
Cochrane Protocol (Louie 2000).
Types of interventions
Vaccination with any PPV. We included studies making the fol-
lowing comparisons:
• vaccine compared with placebo;
• vaccine compared with no intervention; and
• a combination of pneumococcal vaccine with a non-
pneumococcal vaccine compared with the other vaccine given
alone.
Where reported, we limited disease outcomes to those occurring
14 days or more after vaccination.
Types of outcome measures
Primary outcomes
A. RCTs
• A1. IPD: a pneumococcal infection with S. pneumoniae
isolated from a usually sterile body fluid.
• A2. Pneumonia (all-cause): clinically and radiographically
confirmed pneumonia, independent of the cause of pneumonia.
• A3. Mortality (all-cause).
Secondary outcomes
• A4. IPD (as defined in A1): of a pneumococcal serotype
included in the vaccine administered.
• A5. Definitive pneumococcal pneumonia: clinically and
radiographically confirmed pneumonia with S. pneumoniae
isolated from a usually sterile site.
• A6. Definitive pneumococcal pneumonia (as defined in
A5): of a pneumococcal serotype included in the vaccine
administered.
• A7. Presumptive pneumococcal pneumonia: clinically and
radiographically confirmed pneumonia with S. pneumoniae
isolated from a culture of sputum or a nasal swab.
• A8. Presumptive pneumococcal pneumonia (as defined in
A7): of a pneumococcal serotype included in the vaccine
administered.
• A9. Mortality due to pneumonia (pneumonia as defined in
A2).
• A10. Mortality due to pneumococcal infection (as defined
in A1).
• A11. Pneumococcal nasopharyngeal colonisation: defined
as the detection of S. pneumoniae isolated from a culture from a
nose or nasopharyngeal swab.
B. Non-RCTs
• B1. IPD: a pneumococcal infection with S. pneumoniae
isolated from a usually sterile site.
• B2. IPD (as defined in B1): of a pneumococcal serotype
included in the vaccine administered.
Search methods for identification of studies
Electronic searches
For this review update we searched the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) 2012, Issue 6, part of The
Cochrane Library, www.thecochranelibrary.com (accessed 22 June
2012), which contains the Acute Respiratory Infections (ARI)
Group’s Specialised Register, MEDLINE (from 01 April 2007 to
June Week 2, 2012) and EMBASE (from 01 April 2007 to June
2012).
We used the search strategy detailed in Appendix 1 to search
CENTRAL and MEDLINE for randomised trials. We combined
the MEDLINE search strategy with the Cochrane Highly Sen-
sitive Search Strategy for identifying randomised trials in MED-
LINE: sensitivity- and precision-maximising version (2008 revi-
sion); Ovid format (Lefebvre 2011). We adapted the search strat-
egy to search EMBASE (Appendix 2).
To identify non-randomised studies we adapted the search strat-
egy devised by Fraser (Fraser 2006) to search MEDLINE (see
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Appendix 3) and EMBASE (Appendix 4). We did not use any
language or publication restrictions.
Searching other resources
We did not search additional resources for this update. Please see
Appendix 5 for details of the previous searches.
Data collection and analysis
Selection of studies
Two review authors independently reviewed the full text of studies
retrieved by the electronic searches for both the RCTs and non-
RCTs (JH, DT and SM, RA, respectively) that appeared to meet
the inclusion criteria from the abstract.
Data extraction and management
Two review authors independently extracted data from the RCTs
and non-RCTs (JH, DT and SM, RA, respectively) from the pub-
lished reports using standardised data extraction forms. We col-
lected study details and outcome data and outlined them in the
Characteristics of included studies table.
Assessment of risk of bias in included studies
We assessed the risk of bias of the included studies according to the
Cochrane ’Risk of bias’ tool (Higgins 2011). Two review authors
independently assessed the risk of bias of included RCTs and non-
RCTs (JH, DT and SM, RA, respectively). We discussed any in-
consistency in the scores so as to agree on a final score. We scored
each trial on the following criteria:
Sequence generation
• Low risk of bias, if the allocation sequence was generated by
a computer, a random number table, or similar.
• Uncertain risk of bias, if the trial was described as
randomised but the method used for the allocation sequence
generation was not described.
• High risk of bias, if an inadequate system was used for the
allocation of patients (such as a non-randomised study).
Allocation concealment
• Low risk of bias, if the allocation of participants involved a
central independent unit; on-site locked computer; or
consecutively numbered, sealed envelopes for a randomised
study and if study investigators determining participant
inclusion unlikely to be aware of vaccination status for non-
randomised studies.
• Uncertain risk of bias, if the trial was described as
randomised but the method used to conceal the allocation was
not described.
• High risk of bias, if the allocation sequence was known to
the investigators who assigned participants.
Blinding of participants and personnel
• Low risk of bias, if study participants and study personnel
were blinded and the method of blinding was described.
• Uncertain risk of bias, if study participants and study
personnel were blinded and the method of blinding was not
described.
• High risk of bias, if the study participants or study
personnel were not blinded.
Blinding of outcome assessors
• Low risk of bias, if the outcome assessors were blinded and
the method of blinding was described.
• Uncertain risk of bias, if the outcome assessors were blinded
and the method of blinding was not described.
• High risk of bias, if the outcome assessors were not blinded.
Incomplete data outcomes
• Low risk of bias, if any post-randomisation drop-outs or
withdrawals, if they occurred, were clearly described and the
reasons described.
• Uncertain risk of bias, if it was not clear whether there were
any drop-outs or withdrawals or if the reasons for these drop-
outs were not clear.
• High risk of bias, if the reasons for missing data were likely
to be related to the outcomes, such as if ‘as-treated’ analysis was
performed; or patients with missing data were likely to induce
clinically relevant bias in vaccination effect size.
Selective outcome reporting
• Low risk of bias, if all the predefined (primary and
secondary) outcomes mentioned in the trials’ protocol or in the
design article were reported and the reporting had been done in
the prespecified way.
• Uncertain risk of bias, if there was insufficient information
to assess whether a risk of selective outcome reporting was
present.
• High risk of bias, if not all the prespecified outcomes were
reported, if the primary outcomes were changed, or if some of
the important outcomes were incompletely reported.
Besides investigating each bias domain, we also evaluated the over-
all risk of bias for the study.Whenwe judged sequence generation,
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allocation concealment and blinding criteria to be low risk, we
classified the study as being at overall low risk of bias.
In addition to the above criteria, we assessed non-RCTs for their
control of confounding factors. We determined a pre-determined
list of important confounders (age, sex, smoking status, chronic
illness, nursing home residence and influenza vaccination status).
Judgement included consideration of the proportion of important
confounding factors, whether the most important confounders
were considered and balance of these between groups at baseline.
A study was assessed as:
• low risk of bias, if all important confounding factors were
balanced at baseline or measured and controlled for in the
analysis;
• uncertain risk of bias, if the control of confounding factors
was not described (these studies would have been excluded); and
• high risk of bias, if the most important confounding factors
were not adequately controlled for (these studies would have also
have been excluded).
Measures of treatment effect
For the analysis of RCTs, we summarised vaccine efficacy as odds
ratios (ORs) and 95% confidence intervals (CIs). We used ran-
dom-effects models. We examined publication bias using funnel
plots. For the analysis of non-RCTs, we summarised effectiveness
following the conversion of each study outcome to a log OR and
standard error (SE). We used random-effects models. We con-
ducted analyses using RevMan 2011. Where results were also pre-
sented as estimates of vaccine effectiveness, this has been calcu-
lated as 100 (1 - pooled OR). This formula has also been used
for the RCT component of the review, as an approximation for
vaccine efficacy, as the risk of the included outcomes is so low.
The rationale for using OR was based on the inclusion of non-
randomised studies (such as matched case-control studies), where
a simple comparison of the number of cases in vaccinated com-
pared to unvaccinated is invalid.
Unit of analysis issues
We analyzedRCTand non-RCTs separately. There were no special
issues in the analysis of studies with non-standard designs.
Dealing with missing data
Whenever we identified non-reporting or partial reporting of data
we attempted to contact the corresponding trial author and re-
quested missing data.
Assessment of heterogeneity
We calculated the I2 statistic for each pooled estimate to assess the
effect of statistical heterogeneity.
Assessment of reporting biases
We assessed possible publication bias through visual inspection of
funnel plots.
Data synthesis
We pooled studies regardless of which vaccine valency was utilised
within the study. We used random-effect models throughout to
take account of the between-study variance in our findings.
Subgroup analysis and investigation of heterogeneity
A. RCTs
We conducted a subgroup analysis of the RCTs according to pre-
specified characteristics of trials that were considered clinically rel-
evant and would lead to recommendations for vaccination accord-
ing to populations at risk of pneumococcal disease due to differ-
ent factors. True pre-specification was not possible due to authors’
prior knowledge of trials but was conducted prior to determining
the number of participants in each group. We conducted an anal-
ysis for the following three subgroups of participants.
1. Otherwise healthy adults in low-income countries. This
population group included otherwise healthy adults who were
likely to be at greater risk of pneumococcal disease than their
counterparts in high-income countries due to environmental
factors such as overcrowding and exposure to smoke, together
with likely differences in serotype distribution.
2. Adults with chronic illness in high-income countries. This
population group was likely to be at elevated susceptibility to
disease and potentially had suboptimal vaccine immunogenicity.
3. Otherwise healthy adults in high-income countries. This
population group included participants from high-income
countries who were not recruited on the basis of underlying
disease. We refer to these participants as ’otherwise healthy
adults’ and expected that they may have a better immune
response to vaccination than their counterparts in subgroup ii).
We performed this subgroup analysis for the primary outcomes
that included the larger number of studies (at least 10).We investi-
gated differences between subgroups according to the method de-
scribed by Deeks 2001 whereby significance of difference between
groups was measured by Chi2 = Chi2IPDAll - (Chi2IPDGrp1 + Chi
2
IPDGrp2 + Chi2IPDGrp3).
B. Non-RCTs
We conducted subgroup analysis of the non-RCTs according to
study type (case-control or indirect cohort study compared to co-
hort study) using the methods described by Deeks 2001. Case-
control studies are thought to be more susceptible to bias and, as
such, may give an elevated protective effect. We performed anal-
yses on two subgroups of participants from non-RCTs:
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1. studies on immunocompetent participants; and
2. studies on immunocompetent older adults.
Study participants were considered immunocompetent if they
were not severely immunocompromised. Unless they could be
identified within the study, non-RCTs that included immuno-
compromised participants (those with haematologic cancers, or
receiving prednisolone) were excluded from this analysis. Study
participants were considered to be immunocompetent older adults
if theymet the immunocompetent definition (above) and all study
participants were above 55 years of age, or if adjusted analysis for
this age group was reported.
Sensitivity analysis
We conducted sensitivity analysis on studies deemed to have an
overall low risk of bias and studies not utilising influenza vaccine
as a control vaccine (since this vaccine may potentially have had a
beneficial effect on the outcomes of interest (Jefferson 2010) for
the primary outcomes of the review (IPD, all-cause pneumonia
and all-cause mortality).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
For this updated review, we screened a total of 1817 (299 RCTs
and 1518 non-RCTs) titles from the databases searched (Cochrane
Central Register of Controlled Trials (CENTRAL) 2012, Issue 6,
MEDLINE (January 1966 to June Week 2, 2012) and EMBASE
(1974 to June 2012) (Appendix 1; Appendix 2; Appendix 3;
Appendix 4). We reviewed 19 studies in full text (six RCTs and
13 non-RCTs). Three additional RCTs met our inclusion criteria
and have been considered in this updated review (Furomoto 2008;
Kawakami 2010; Maruyama 2010), bringing the total number of
included studies to 25 (18 RCTs involving 64,901 participants
and seven non-RCTs involving 62,294 participants). In addition,
a publication by Klugman (Klugman 2011) reported additional
data for a study that was already included in the review (Austrian
1976a). Further details on individual trials are provided in the
Characteristics of included studies tables.
Included studies
A. RCTs
The RCTs included in the meta-analysis were conducted among
diverse population groups, which we have classified into three sub-
groups. Firstly, otherwise healthy adults from low-income coun-
tries; this group consisted of African mine workers (Austrian
1976a; Smit 1977a; Smit 1977b) and community-dwelling adults
residing in the highlands of Papua NewGuinea (Riley 1977), con-
sidered to have been at elevated risk of disease due to overcrowding
and environmental factors. These studieswere conductedwith vac-
cines containing six to 14 pneumococcal polysaccharide serotypes.
The second group were those populations that were considered
to be at elevated risk of pneumococcal disease due to underlying
medical illnesses such as chronic obstructive pulmonary disease
(Alfageme 2006; Davis 1987; Furomoto 2008; Kawakami 2010;
Leech 1987) or patients with bronchogenic carcinoma (Klastersky
1986). Simberkoff 1986 recruited participants on the basis of age
(> 55 years) and the presence of underlying chronic illness. Given
the number of deaths in both participant groups, this group was
considered very high risk. Collectively, these studies utilised either
the 14-valent or 23-valent PPVs in developed country settings:
Spain, USA, Canada, Belgium, Japan and Denmark.
The third population group of the included RCTs were partic-
ipants in high-income countries who were not recruited on the
basis of underlying disease. These studies were conducted with
vaccines containing two to 23-valent pneumococcal polysaccha-
ride serotypes. The studies included participants at elevated risk of
pneumococcal disease due to their age and place of residence; in-
stitution-based in New York (Kaufman 1947), hospices or retire-
ments homes (Gaillat 1985; Maruyama 2010); older adults aged
50 to 85 years with previous hospital admission for community-
acquired pneumonia in Sweden (Ortqvist 1998); and community-
based older adults in Finland (Koivula 1997). The two other trials
were conducted in the United States among participants whose
ages were not specified: adult inpatients were recruited from a psy-
chiatric hospital (Austrian 1980a); and adults members were re-
cruited from theKaiser PermanenteHealth Plan (Austrian 1980b).
The most commonly reported outcome from the RCTs was all-
cause radiologically confirmed pneumonia (16 studies) followed
by all-cause mortality (14 studies) and IPD (11 studies). Five
studies reported on vaccine-type IPD and four studies reported
outcomes on vaccine-type definitive pneumonia. Mortality due
to pneumonia was reported in nine studies and pneumococcal-
specific mortality was reported in four studies. Pneumococcal na-
sopharyngeal colonisation was an outcome in two of the included
studies but could not be included in this review due to incomplete
reporting.
B. Non-RCTs
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Five case-control studies and two large cohort studies were in-
cluded in the meta-analysis of non-RCTs. They considered the
14-valent and 23-valent PPVs.
Three case-control studies that were set in the United States in-
cluded participants aged from 18 years with medical conditions
that placed them at higher risk of pneumococcal disease, or partic-
ipants who were above 65 years of age (Benin 2003; Shapiro 1984;
Shapiro 1991). The other two case-control studies related only to
older adults: Sims 1988 recruited immunocompetent adults from
55 years of age (United States); and Dominguez 2005 included
older adults from 65 years of age (Spain). The two cohort studies
both contained large numbers of participants aged 65 years and
above. One assessed 47,365 members of a GroupHealth Co-oper-
ative in the United States, over a three-year period (Jackson 2003);
the other followed up 11,241 community-dwelling Spanish resi-
dents for just over three years (Vila-Corcoles 2006). Both of these
studies considered the 23-valent PPV.
Excluded studies
For this update, we excluded three RCTs and 13 non-RCTs (please
see Characteristics of excluded studies). Two RCTs were excluded
as theywere only available in abstract form, where a full assessment
of outcome definitions or trial quality could not be determined (
Teramoto 2007; YaTseimakh 2006).OneRCTwas excluded as we
were unable to separate the role of steroids in the study (Steentoft
2007). All non-RCTswere excluded due to not considering culture
confirmed IPD as an outcome, including one study which used
ICD codes to diagnose IPD.
Risk of bias in included studies
The risk of bias in included studies is described within the
Characteristics of included studies tables and summarised graph-
ically in Figure 1 and Figure 2.
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Figure 1. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
randomised study.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
non-randomised study.
10Vaccines for preventing pneumococcal infection in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Most RCTs scored poorly across the factors assessed and only four
trials were deemed to have an overall low risk of bias (Austrian
1980b; Maruyama 2010; Ortqvist 1998; Riley 1977).
Thirty-nine per cent of trials described an adequate method of
sequence generation and allocation concealment, 44% of trials
reported adequate blinding of participants and personnel and 67%
reported adequate blinding of outcome assessors, 22% scored low
risk of bias for incomplete outcome data, and 17% scored low risk
of bias on selective reporting.
The poor scores were more common in the earlier trials and were
largely due to inadequate reporting rather than known inadequate
methods.
Non-RCTs
Non-RCTs scored low risk of bias against allocation concealment
(as adequate control of confounding factors was a study inclu-
sion criterion). The predetermined important confounding fac-
tors were age, chronic illness, smoking, influenza vaccination and
nursing home residency (Table 1). The five case-control studies
matched participants according to the presence of underlying dis-
ease (severity and number of conditions) and date of hospital ad-
mission. All studies apart from Sims 1988 reported matching ac-
cording to age.
Both cohort studies followed participants for three years and con-
trolled for age, sex and underlying medical conditions; they in-
cluded compromised immune status, smoking status and influenza
vaccination status in the model of effectiveness of PPV. Vaccina-
tion was a time variable factor and participants were considered to
be vaccinated 14 days following vaccine administration.
Effects of interventions
A. Randomised controlled trials (RCTs)
Outcome A1. Invasive pneumococcal disease (IPD)
We included 11 studies involving 36,489 participants for this out-
come, with 15 events in the vaccinated group and 63 events in
the control group. Pneumococcal polysaccharide vaccine (PPV)
reduced the risk of all IPD with a pooled estimated odds ratio
(OR) of 0.26 (95% confidence interval (CI) 0.14 to 0.45; ran-
dom-effects model), that is, a protective vaccine efficacy of 74%
(95% CI 55% to 86%). Statistical heterogeneity was not present
(I2 = 0%, P = 0.56).
Subgroups: outcome A1
(i) Otherwise healthy adults in low-income countries
Riley 1977 was the only study included in this subgroup analysis,
involving 5373 participants with two events in the vaccinated
group compared to 14 events in the control group. There was
evidence of protective efficacy against IPD for this subgroup with
OR 0.14 (95% CI 0.03 to 0.61).
(ii) Adults with chronic disease in high-income countries
Five studies involving 3230 participants were included in this sub-
group analysis with four events in the vaccinated group compared
to two events in the control group. There was no evidence of pro-
tective efficacy (or any harm) from vaccination against IPD in this
subgroup. However, as demonstrated by the large CIs, there was a
lack of power to demonstrate a significant difference between the
vaccinated group and the control groups (OR 1.56, 95% CI 0.35
to 6.94; random-effects model, I2 = 0%).
(iii) Otherwise healthy adults in high-income countries
Five studies involving 27,886 participants were included in this
subgroup analysis with nine events in the vaccinated group and
47 events in the control group. There was evidence of protective
efficacy against IPD in this subgroup (OR 0.20, 95% CI 0.10 to
0.39; random-effects model, I2 = 0%).
The difference between the heterogeneity for all studies compared
to subgroups i, ii and iii was statistically significant (Chi2 = 6.7,
1 df, P < 0.01) indicating that the pooled estimate may not be
representative for each population group.
Outcome A2. Pneumonia (all-cause)
We included 16 studies involving 47,734 participants for this out-
come, with 978 events in the vaccinated group and 1547 events in
the control group. PPV was shown to be effective against all-cause
pneumonia with a pooled estimated OR of 0.72 (95% CI 0.56 to
0.93; random-effects model). However, there was a high level of
statistical heterogeneity present amongst the included studies (I2
= 85%, P < 0.00001).
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Subgroups: outcome A2
(i) Adults in low-income countries
Four studies involving 14,562 participants were included in this
subgroup analysis with 158 events in the vaccinated group com-
pared to 548 events in the control group. Pooled estimates showed
evidence of protective efficacy against all-cause pneumonia in this
population subgroup (OR 0.54, 95% CI 0.43 to 0.67; random-
effects model, I2 = 19%).
(ii) Adults with chronic illness in high-income countries
Six studies involving 4010 participants were included in this sub-
group analysis with 170 events in the vaccinated group compared
to 181 events in the control group. As with other outcomes in
this population subgroup, wide CIs highlighted the lack of power
to demonstrate protective efficacy (or lack thereof ) against all-
cause pneumonia (OR 0.93, 95%CI 0.73 to 1.19; random-effects
model, I2 = 10%).
(iii) Adults in high-income countries
Six studies involving 29,186 participants were included in this
subgroup analysis with 650 events in the vaccinated group and 818
events in the control group. There was no evidence of protective
efficacy against all-cause pneumonia for this subgroup, although
it again should be noted that the CIs were wide (OR 0.71, 95%
CI 0.45 to 1.12; random-effects model). There was also a high
level of statistical heterogeneity present (I2 = 93%).
As with IPD, the difference between the heterogeneity for all stud-
ies compared to groups i, ii and iii was statistically significant (Chi
2 19.23, 2 df, P < 0.001), indicating that the pooled estimate may
not be representative for each population group.
Outcome A3. Mortality (all-cause)
We included 14 studies involving 47,560 participants for this out-
come, with 1018 events in the vaccinated group and 1039 in the
control group. There was no evidence of protective efficacy against
all-cause mortality, with a pooled estimated OR of 0.90 (95% CI
0.74 to 1.09; random-effects model). A high level of statistical
heterogeneity was present (I2 = 69%, P < 0.0001).
Subgroups: outcome A3
(i) Adults in low-income countries
Riley 1977 was the only study included in this subgroup, involving
11,958 participants with 133 events in the vaccine group and 170
in the control group (OR 0.79, 95% CI 0.62 to 0.99).
(ii) Adults with chronic illness in high-income countries
Six studies involving 3603 participants were included in this sub-
group analysis with 263 events in the vaccinated group compared
to 231 events in the control group. Whilst there were more deaths
in the vaccinated group than in the control group the pooled es-
timate failed to demonstrate protective efficacy (or harm) in this
subgroup (OR 1.13, 95% CI 0.90 to 1.43; random-effects model,
I2 = 6%).
(iii) Adults in high-income countries
Seven studies involving 32,023 participants were included in this
subgroup analysis with 622 events in the vaccinated group and 638
events in the control group. There was no evidence of a protective
effect against all-cause mortality with a pooled estimated OR of
0.88 (95% CI 0.67 to 1.17; random-effects model, I2 = 79%).
As with IPD and all-cause pneumonia, the difference between the
heterogeneity for all studies compared to groups i, ii and iii was
statistically significant (Chi2 = 7.49, 1 df, P < 0.05), indicating that
the pooled estimate may not be representative for each population
group.
Secondary outcomes
IPD (subgroups)
Outcome A4. Vaccine-type IPD
We included five studies involving 31,223 participants for this
outcome, with 14 events in the vaccinated group and 140 in the
control group. The pooled estimate showed vaccination to be ef-
fective for this very specific outcome (OR 0.18, 95% CI 0.10 to
0.31). Statistical heterogeneity was absent (I2 = 0%, P = 0.70).
Outcome A5. Definitive pneumococcal pneumonia
We included 10 studies involving 35,483 participants for this out-
come, with 15 events in the vaccinated group compared to 60
events in the control group. PPV reduced the risk of definitive
pneumococcal pneumonia, with a pooled estimated OR of 0.26
(95%CI 0.15 to 0.46; random-effects model). The protective vac-
cine efficacy of 74% (95% CI 54% to 85%) was very similar to
the size of the effect for outcome A1, which is likely to be due
to the large amount of overlap for studies contributing to both
outcomes. Statistical heterogeneity was absent (I2 = 0%, P = 0.48).
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Outcome A6. Definitive PPV (vaccine-types only)
We included four studies involving 30,561 participants for this
outcome, with three events in the vaccinated group and 30 events
in the control group. The pooled estimate showed the vaccine to
be highly effective for this outcome (OR 0.13, 95% CI 0.05 to
0.38; random-effects model). Statistical heterogeneity was absent
(I2 = 0%, P = 0.92).
All-cause pneumonia (subgroups)
Outcome A7. Presumptive pneumococcal pneumonia
We included nine studies involving 20,335 participants for this
outcome, with 100 events in the vaccinated group and 276 in the
control group. The pooled estimate showed the vaccine to be ef-
fective against this outcome (OR 0.46, 95% CI 0.25 to 0.84; ran-
dom-effects model). As with all-cause pneumonia, a high level of
statistical heterogeneitywas present among the studies included for
presumptive pneumococcal pneumonia (I2 = 75%, P < 0.0001).
Outcome A8. Presumptive pneumococcal pneumonia
(vaccine-types only)
We included five studies involving 18,568 participants for this
outcome, with 19 events in the vaccinated group and 130 in the
control group. The pooled estimate showed vaccination was ef-
fective against this outcome with an OR of 0.27 (95% CI 0.08
to 0.87; random-effects model). Again a high level of statistical
heterogeneity was present (I2 = 70%, P = 0.01).
All-cause mortality (subgroups)
Outcome A9. Mortality due to pneumonia
We included nine studies involving 30,723 participants for this
outcome, with 135 events in the vaccinated group and 221 events
in the control group. However, the pooled estimate failed to
demonstrate protective efficacy against pneumonia-related mor-
tality (OR0.71, 95%CI 0.44 to 1.16; random-effectsmodel) with
a high level of statistical heterogeneity again present (I2 = 72%, P
= 0.0004).
Outcome A10. Mortality due to pneumococcal infection
We included three studies involving 2445 participants for this
outcome, with five events in the vaccinated group compared to one
event in the control group. Given the small number of events for
the sample size, there was insufficient power to demonstrate either
a reduction or increase in the risk of death from pneumococcal
infection among those who had been vaccinated (OR 2.51, 95%
CI 0.45 to 14.13; random-effects model; I2 = 0%).
Outcome A11. Pneumococcal nasopharyngeal colonisation
Although three studies reported outcomes for pneumococ-
cal nasopharyngeal colonisation (Austrian 1976a; Riley 1977;
Simberkoff 1986) neither could be included in the meta-analysis
of this outcome. Riley 1977 reported on a subgroup of healthy
persons (151/2713 vaccine recipients and 181/2660 placebo re-
cipients) but gave no details on how this subgroup had been se-
lected. Simberkoff 1986 reported data on 10,961 throat swabs
taken from 2295 participants. Fifty-four vaccine recipients and
56 placebo recipients were reported as having transient colonisa-
tion but no details were given for prevalence of colonisation across
the two groups for one time period. Klugman 2011 reported data
from the Austrian study (Austrian 1976a) demonstrating a lower
rate of vaccine type carriage as a proportion of any pneumococcal
carriage (excluding serotype 3) in six and 13-valent vaccine re-
cipients compared to both the meningococcal and saline control
group respectively (11/160, 6.9% compared to 33/144, 22.9% (P
< 0.001) and 26/113 23% (P = 0.002) and 6/33, 18.3% com-
pared to 10/28, 35.7% (P = 0.15) and 18/35, 51% (P = 0.0054)
respectively). These data could not be included in a meta-analysis
as no individual denominator data are provided.
Sensitivity analysis on RCTs
Quality score
For the sensitivity analysis based on trial risk of bias, only Austrian
1980b, Maruyama 2010, Ortqvist 1998 and Riley 1977 scored
as overall low risk of bias. Retaining only these trials deemed to
have a ‘low risk of bias’ did not alter the significantly protective ef-
fect against IPD but the significance of the effect against all-cause
pneumonia was lost. For all-cause pneumonia, the level of statis-
tical heterogeneity remained high. All-cause mortality remained
non-significant when limited to those trials deemed to have a ‘low
risk of bias’.
Outcome A1. IPD
OR 0.15 (95% CI 0.05 to 0.43; random-effects model, I2 = 0%).
Outcome A2. All-cause pneumonia
OR0.82 (95%CI 0.59 to 1.14; random-effects model, I2 = 76%).
Outcome A3. All-cause mortality
OR0.93 (95%CI 0.77 to 1.13; random-effects model, I2 = 22%).
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Influenza vaccine as a control
Five included studies used influenza vaccine. Two studies (Koivula
1997; Leech 1987) gave the vaccine to both PPV intervention
and control participants and as such are only able to measure
the incremental benefit of pneumococcal vaccination. Furomoto
2008, Gaillat 1985 and Kawakami 2010 used influenza vaccine in
control participants only. Following the exclusion of these three
studies, the estimate of protective effects of PPV against IPD and
pneumonia remained significant. The result for all-cause mortal-
ity was only slightly affected. The level of statistical heterogeneity
remained high for both all-cause pneumonia and all-cause mor-
tality.
Outcome A1. IPD
OR 0.25 (95% CI 0.14 to 0.45; random-effects model, I2 = 0%).
Outcome A2. All-cause pneumonia
OR0.73 (95%CI 0.55 to 0.97; random-effects model, I2 = 87%).
Outcome A3. All-cause mortality
OR0.88 (95%CI 0.69 to 1.11; random-effects model, I2 = 75%).
Publication (small study) bias
We assessed publication bias using funnel plots and presented this
for the three primary outcomes of IPD, all-cause pneumonia and
all-cause mortality. For each of these outcomes the funnel plots
were asymmetrical.
The funnel plot of studies contributing to the outcome of IPD
(Figure 3) showed asymmetry around the pooled point estimate.
However, it was not the smaller studies contributing larger treat-
ment effects and, therefore, asymmetrymay be due to other factors
such as heterogeneity between the population groups.
Figure 3. Funnel plot for outcome 1. Invasive pneumococcal disease
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The funnel plot of studies contributing to the outcome of all-
cause pneumonia (Figure 4) also showed asymmetry around the
pooled point estimate. There was an absence of smaller studies
contributing less effective outcomes. This did not appear to be
having a large impact on the pooled result as the larger studies
appeared to be symmetrical around no effect.
Figure 4. Funnel plot for outcome 2. Pneumonia, all causes
The funnel plot of studies contributing to the outcome of all-cause
mortality (Figure 5) also showed asymmetry around the pooled
point estimate. Kaufman 1947 was a clear outlier and two other
smaller studies show a larger effect but again these studies did not
appear to have a large impact on the pooled results.
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Figure 5. Funnel plot for outcome 3. Mortality, all causes
B. Non-RCTs
Outcome B1. IPD
Seven studies were included in this outcome. PPV reduced the
risk of all IPD with a pooled estimate OR of 0.48 (95% CI 0.37
to 0.61; random-effects model). Statistical heterogeneity was low
(I2 = 31.4%, P = 0.19).
Subgroup outcome B1. Immunocompetent
A subgroup analysis of immunocompetent participants included
six studies. PPV reduced the risk of all IPD in immunocompe-
tent adults with a pooled estimated OR of 0.41 (95% CI 0.32 to
0.52; random-effects model). Statistical heterogeneity was low (I
2 = 18%, P = 0.30).
Subgroup outcome B1. Immunocompetent older adults
A subgroup analysis of immunocompetent older adults included
five studies. PPV reduced the risk of all IPD in immunocompetent
older adults with a pooled estimated OR of 0.32 (95% CI 0.22 to
0.47; random-effects model). Statistical heterogeneity was absent
(I2 = 0%, P = 0.68).
Subgroup analysis of study type
Subgroup analysis for IPD (all types) was conducted by study type
(case-control or cohort). For case-control studies, the pooled esti-
mate of vaccine effectiveness was not significantly different from
that determined from the cohort studies (OR 0.47, 95% CI 0.32
to 0.68; and OR 0.57, 95% CI 0.36 to 0.89, respectively). The
difference between the heterogeneity for all studies compared to
case-control and cohort studies did not reach statistical signifi-
cance (Chi2 = 2.13, 1 df, P > 0.1).
Outcome B2. Vaccine-type IPD
Three studies were included in this outcome, with a pooled esti-
mated OR of 0.45 (95% CI 0.38 to 0.54; random-effects model;
I2 = 0%). The estimate for this outcome was similar to that for all
studies, although with a narrower CI.
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Subgroup outcome B2. Immunocompetent
Of the two studies that considered vaccine-type IPD in immuno-
competent participants, pooled results showed an OR of 0.40
(95% CI 0.29 to 0.54; random-effects model; I2 = 0%).
Subgroup outcome B2. Immunocompetent older adults
Only one study reported on vaccine-type IPD in immunocom-
petent older adults, with a non-significant protective effect (OR
0.66, 95% CI 0.14 to 3.03).
D I S C U S S I O N
In this review we aimed to determine the efficacy/effectiveness of
the pneumococcal polysaccharide vaccine (PPV), a vaccine that in
its current format has been licensed for nearly 30 years in adults.
Given that most large randomised controlled trials (RCTs) had
been conducted in populations with significant differences in dis-
ease susceptibility and serotype distribution, the clinical relevance
to adult populations today appears to be uncertain. Nevertheless,
we have attempted to define clinically relevant primary outcomes
and conducted analysis in distinct population groups that are likely
to differ in disease susceptibility and disease exposure.
Summary of main results
Invasive pneumococcal disease (IPD)
This meta-analysis demonstrates strong evidence of protection
against IPD, with a correlate of efficacy from the RCTs of 74%
(95% confidence interval (CI) 56% to 85%). This result remained
robust in sensitivity analyses based on trial quality and influenza
vaccine use.
Although therewas no statistical heterogeneitywhen all RCTswere
considered, there was a statistical difference (P < 0.01) between
the heterogeneity of the studies conducted among different popu-
lation groups (otherwise healthy adults in low-income countries,
adults with chronic illness in high-income countries and otherwise
healthy adults in high-income countries). This indicates that the
estimate of efficacy generated from pooling all of the studies is
not representative for each of these population groups. In particu-
lar, vaccine efficacy amongst the subgroup of adults with chronic
disease appears poor in comparison to that of otherwise healthy
adults, in developed or low-income countries. Whilst there was
insufficient power to demonstrate protective efficacy among the
subgroup of adults with chronic disease, it should be noted that
the disease risk amongst the control group was 124 per 100,000
population (2/1619). This is within the general estimate of IPD
for older adults (50 cases per 100,000 population) (Fedson 1999)
and indicates these studies are underpowered due to the number of
participants recruited rather than low disease incidence. Evidence
for vaccine effectiveness against IPD in this subgroup population
is considered in the non-RCTs.
The inclusion of non-RCTs in this meta-analysis provides a valu-
able contribution to the understanding of the effectiveness of the
PPV, used more recently in large population groups for whom the
vaccine is currently recommended. The meta-analysis of the non-
RCTs demonstrated protective effectiveness against IPD with a
pooled estimate corresponding to a slightly lower measure of vac-
cine effectiveness of 52% (95% CI 37% to 61%) for all serotypes
and 55% (95% CI 38% to 54%) for vaccine-type disease.
Effectiveness among both immunocompetent adults and im-
munocompetent older adults was also shown, with a non-signif-
icantly higher estimate of effectiveness of 59% for all serotypes
(95%CI 48% to 68%).We assessed case-control studies separately
from cohort studies and showed that the estimate of effectiveness
from pooled case-control studies, at 53% (95% CI 32% to 68%),
was not dissimilar to that obtained from the two large cohort stud-
ies (43%, 95% CI 11% to 64%).
The case-control studies had similar estimates for vaccine effec-
tiveness (70%, 67% and 70%) with the exception of the Benin
2003 study among Navajo adults. Benin 2003, involving persons
aged from 18 years who had a medical condition that placed them
at higher risk of pneumococcal disease, or others from age 65 years,
found vaccine effectiveness of only 27%. The inferior estimate of
effectiveness among Navajo adults may be due to population char-
acteristics. It was reported that 75% of cases and 78% of controls
were assigned as risk level 2 (alcoholism, diabetes, chronic cardiac,
lung, renal and liver disease). This is higher than the equivalent
disease risk ratings of the other case-control studies. Alcoholism in
particular is very prevalent in participants in the Benin 2003 study
(43% and 45% of cases and controls), which has been associated
with poor vaccine immunogenicity (Butler 1993) and vaccine fail-
ures (Hanna 2000; McMahon 1993).
Both the Jackson 2003 and Vila-Corcoles 2006 cohort studies
report very similar multivariate adjusted hazard ratios (HRs) for
all-type IPDof 0.56 (95%CI0.33 to 0.93) and 0.60 (95%CI 0.22
to 1.65) respectively. Both studies adjusted for receipt of influenza
vaccination.
All-cause pneumonia
All-cause pneumonia was the most reported outcome in this re-
view with data from 16 RCTs. The pooled estimate of vaccine
efficacy was 28% (95% CI 7% to 44%) but there was substantial
variability in the effect estimate due to heterogeneity (I2 = 85%,
P < 0.0001). Given the substantial proportion of variability due
to heterogeneity, the available evidence does not demonstrate that
PPVs prevent all-cause pneumonia in adults.
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In contrast, we did find evidence of benefit against all-cause pneu-
monia among otherwise healthy adults in low-income countries
(subgroup analysis). Here the pooled estimate of vaccine efficacy
was supported by low heterogeneity (vaccine efficacy = 46%, 95%
CI 33% to 57%, I2 = 19%, P value for heterogeneity was 0.29).
The point estimate for other population subgroups, adults with
chronic illness and otherwise healthy adults from high-income
countries, were inconclusive. For those with chronic illness there
was a low level of heterogeneity (I2 = 10%) but vaccine efficacy was
7% (-19% to 27%). A comparison of heterogeneity between these
groups and the total pooled estimate was statistically significant
(P < 0.001), which also supports the conclusion that the overall
estimate of effectiveness is not applicable to all population groups,
who are at different risk and susceptibility to disease.
With the upper limit of the CI of the odds ratio (OR) at 0.93, ex-
cluding any study from this analysis results in a loss of significance
(including sensitivity analysis based on trial quality). It should be
acknowledged that the meta-analysis is inadequately powered to
exclude a protective efficacy of less than 44%. This has been a
consistent criticism of previous meta-analyses that remains valid
in this updated review.
All-cause mortality
This meta-analysis has failed to demonstrate evidence for PPV ef-
fectiveness against mortality (all-cause or pneumococcal-related).
All-cause mortality was reported in 14 studies with no evidence
of a protective benefit from the meta-analysis (OR 0.90, 95% CI
0.74 to 1.09). The statistical heterogeneity (P < 0.0001) of these
pooled studies was again investigated by population group. We
found the differences between otherwise healthy adults in low-in-
come countries, adults with chronic illness in high-income coun-
tries and otherwise healthy adults in high-income countries to be
significant (P < 0.05), suggesting that the pooled estimate of ef-
fectiveness is not applicable to all population groups at different
levels of risk and susceptibility to disease. It should be acknowl-
edged that the meta-analysis is inadequately powered to exclude a
protective efficacy of less than 26%, or a harmful effect less than
9%.
The use of influenza vaccine in three included studies may have in-
fluenced the ability of this meta-analysis to determine the efficacy
of PPV against all-cause mortality. Furomoto 2008, Gaillat 1985
and Kawakami 2010 administered influenza vaccine to control
participants only. The removal of these studies had only a slight
effect on the pooled estimate of all trials in sensitivity analysis.
Koivula 1997 and Leech 1987 gave influenza vaccine to both PPV
intervention and control participants, thereby only had the ability
to show the benefit of PPV against all-cause mortality in addition
to that achieved by influenza vaccination.
Subgroup analysis
Otherwise healthy adults in low-income countries
The combined studies from this relatively homogenous subgroup
of young African miners and Papua New Guinean Highlanders
consistently demonstrate elevated vaccine efficacy against various
outcomes. Of note, vaccine efficacy has been demonstrated for
all-cause pneumonia (four studies) and all-cause mortality (one
study) for this population only. It is also important to highlight
that the settings of these trials meant pneumococcal disease was
likely to be caused by a limited number of serotypes, particularly
in the mines, where pneumococcal outbreaks were a significant
cause of mortality. In addition, the vaccines utilised in these trials
had fewer serotypes and higher antigen content than the currently
licensed 23-valent PPV. These findings highlight potential benefits
of vaccination against pneumonia and death for otherwise healthy
adults in low-income countries. Whether the findings from these
early studies remain directly applicable today will depend on a
range of factors including whether the circulating serotypes match
those in the vaccine, the health status of the population, suscepti-
bility to disease and risk of exposure.
Adults with chronic illness in high-income countries
The subgroup analysis of RCTs in adults recruited on the basis
of the presence of chronic illness in high-income countries con-
sistently failed to demonstrate evidence of protective benefit of
vaccination. For each of the outcomes included in subgroup anal-
ysis there were few events in either the intervention or control
group and CIs were wide. This indicates that the combined studies
remain underpowered. Whilst our review incorporated observa-
tional studies which included control for potential confounding
factors such as chronic disease, we did not directly assess vaccine
effectiveness against IPD for the chronic disease group.
Otherwise healthy adults in high-income countries
The combined studies for this subgroup included participants re-
cruited on the basis of older age or who were likely to be a disad-
vantaged population in high-income countries and demonstrated
consistent evidence for protection against IPD. However, for the
outcomes of all-cause pneumonia and all-causemortality, therewas
a high level of statistical heterogeneity. The heterogeneity within
all-cause pneumonia appears to be predominantly from Gaillat
1985 andKaufman 1947. The remaining four studies do not show
evidence for protection against this outcome. The pooled esti-
mate for all-cause mortality is also statistically heterogeneous, with
Kaufman 1947 being the only study to show protective benefit.
Again, the remaining six studies do not show any evidence for
protection against death within this population group.
Quality of the evidence
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RCTs contributing data to this meta-analysis were conducted over
a considerable period of time (1947 to 2010) and within distinct
population groups, utilising various valencies of the vaccine (with
differing amounts of antigen content). The current 23-valent PPV
has been available since 1983 and was used in 10 of the 24 tri-
als (with known vaccine valency) considered. The quality of the
evidence and applicability of these findings to population groups
currently recommended to receive the 23-valent PPV is consis-
tently strong for protection from invasive pneumococcal disease
but less clear with respect to less specific outcomes, including all-
cause pneumonia.
Potential biases in the review process
The main strengths of the review are the specificity of outcomes
considered. Whilst the review has lost events from studies that
considered less specific definitions, this was unlikely to have sub-
stantially altered the power of the meta-analysis. Considering the
length of time that these vaccines have been licensed, the review is
also strengthened by the inclusion of high-quality non-RCTs for
the further consideration of culture confirmed IPD; which pro-
vided consistent evidence to support findings from the RCTs.
The main weakness of the review remains the lack of power with
which to determine vaccine efficacy against pneumonia. This re-
view also excluded two studies that were available only in abstract
form in order to maintain the quality of the review. Whilst ex-
clusion of non-published data may lead to an over-estimation of
the intervention effect (where less significant results remain un-
published), this is unlikely to have had an influence on this review
as both studies had positive findings for vaccine efficacy against
pneumonia (Teramoto 2007; Ya Tseimakh 2006).
This review did not consider vaccine safety, as it was outside the
scope of the review. The assessment of adverse events following
PPV administrationhas been assessed inmore recent studies (Cook
2007; Jackson 1999; Musher 2010).
Agreements and disagreements with other
studies or reviews
In addition to the previous Cochrane Review (Moberley 2008), at
least seven previous meta-analyses of PPV in adults have been pub-
lished. However, depending on the selection criteria, results from
these meta-analyses have been variable. Controversy continues to
surround the effectiveness and value of the vaccine, particularly
with respect to different disease outcomes and within different
population groups.
A recent meta-analysis by Huss 2009 was based on reporting of
trial quality and has led to calls for withdrawal of the use of 23-
valent PPV in high-risk groups (Jefferson 2009). The most re-
cent and best-quality clinical trials, as determined by Huss 2009,
were conducted post-licensure, largely among populations with
chronic illness or severe immunosuppression, or both. In these
trials, there were very few cases of IPD: seven cases of definitive
pneumococcal pneumonia from two studies and 44 cases of bacter-
aemia from six studies (most of which were among HIV-infected
adults in Uganda). Overall, the findings from theHuss 2009 study
were similar to those presented in this updated Cochrane Review,
with respect to effectiveness against presumptive pneumonia, all-
cause pneumonia and death. However, the primary point of dif-
ference in this updated Cochrane Review is that the protective
effect against IPD remained significant under sensitivity analysis,
when the lower-quality trials were excluded.
Cornu 2001, Moore 2000 and Fine 1994 concluded that the vac-
cine was effective against bacteraemic pneumococcal pneumonia
in ’low-risk’ healthy adults but the RCTs failed to demonstrate vac-
cine efficacy in those at ’high risk’, a heterogeneous group which
included older adults (55 years and above), those with chronic
disease, or the immunosuppressed. Our results also failed to show
evidence for protective efficacy in adults with chronic illness (dis-
cussed below). However, we have further refined this assessment
and have found evidence of efficacy against IPD amongst other-
wise healthy adults in developed country settings. This popula-
tion consisted predominantly of older adults and institutionalised
people.
Hutchison 1999 concluded that there was no evidence that the
vaccine was less efficacious for older adults (55 years and above),
institutionalised people or people with chronic disease. Whilst we
did not directly measure vaccine efficacy against older adults or
institutionalised people, the results of our meta-analysis do high-
light apparent differences in efficacy amongst those participants
selected on the basis of chronic illness, as will be discussed later.
Watson 2002 found the vaccine was effective against mortality and
all-cause pneumonia in non-industrialised countries but not in
industrialised countries and noted that the small number of cases
of pneumococcal bacteraemia made it difficult to draw any firm
conclusions for this outcome. LikeWatson 2002, our results high-
light differences in vaccine efficacy amongst different population
groups. Of particular note is the absence of heterogeneity within
the population subgroups where IPD has been the outcome of in-
terest but when these subgroups where compared against the total
population there was strong evidence of heterogeneity, suggesting
the pooled estimate may not be representative of each population
group.
Puig-Barbera 2002 concluded there was no evidence supporting
pneumococcal vaccine effectiveness to reduce or avoid S. pneumo-
niae disease in older adults (55 years and above) but this meta-
analysis lacked power to adequately assess this outcome, with only
four RCTs included.
Conaty 2004 conducted a systematic review of non-RCTs and
compared results with those from RCTs, finding elevated point
estimates of effectiveness from non-RCTs and non-significant re-
sults from pooled RCTs. Like Conaty 2004 and as with the pre-
vious Cochrane Review (Moberley 2008), this update again in-
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cludes non-RCTs and shows supportive evidence of effectiveness
against IPD. In contrast to both of these meta-analyses, however,
our updated review also demonstrates protective efficacy against
IPD from pooled RCTs.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This meta-analysis supports the use of pneumococcal polysaccha-
ride vaccine (PPV) toprevent invasive pneumococcal disease (IPD)
in adults, particularly otherwise healthy adults, in high-income
and low-income countries. The evidence from our meta-analysis
of randomised controlled trials (RCTs) does not support the rou-
tine use of PPV to prevent all-cause pneumonia or mortality in
adults.
Implications for research
Given the effectiveness of the vaccine in protecting individuals
against IPD, commencing new RCTs in populations at risk where
vaccine effectiveness and disease burden is known would face eth-
ical difficulties, however, the 23-valent PPV may have a place as a
control treatment in RCTs of conjugate or potential protein vac-
cine candidates, which this review does not consider.
We have highlighted the potential differences in vaccine effective-
ness across population groups, where evidence of protective effi-
cacy from RCTs is less clear with respect to adults with chronic
illness. Given adults with chronic illness are the same population
who are targeted for vaccination, further trials assessing vaccine
efficacy against IPD amongst those with chronic disease appear
warranted. However, such trials would need to be large given that
this meta-analysis of five pooled studies remained underpowered
against the rare event of IPD (2/1619 participants in the control
group had the outcome of interest).
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∗ Indicates the major publication for the study
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alfageme 2006
Methods RCT
Participants Participants diagnosed with chronic obstructive airways disease by spirometry at the
University Hospital of Valme, Spain (n = 600). Participants excluded if received previous
pneumococcal vaccination, pregnant, immunosuppressed, in dialysis, HIV+, asplenia
Interventions 23-valent PPV (n = 300) or no vaccine (n = 300). The study ran from 1999 to 2004 and
follow-up was 6 monthly, up to three years
Outcomes A1. IPD
A2. Pneumonia (all causes)
A5. Definitive pneumococcal pneumonia
A7. Presumptive pneumococcal pneumonia
Notes Case ascertainment: participant to contact doctor if temperature greater than 38 C
Primary outcome was time to first episode of CAP
Patients assigned vaccine/no vaccine from a computer-generated random number se-
quence. No reference to blinding
No reference to sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number sequence
Allocation concealment (selection bias) Unclear risk Method not described (nor a placebo used, potentially high risk
of bias)
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described. Participants probably aware due to receipt of 2
vaccines
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physicians participating in the 3-year follow-up were unaware
of the group to which individuals were assigned
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Alfageme 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of incomplete outcome data
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Austrian 1976a
Methods RCT
Participants Young adult male miners in South Africa
Interventions 6-valent PPV first year, 13-valent second year, or Group A meningococcal vaccine or
saline placebo. Total participants across 3 studies n = 12,000
Outcomes A2. Pneumonia (all causes)
A4. IPD (vaccine-type)
Notes Follow-up for 2 years
Participants assigned vaccine/control from table of random numbers
3 trials conducted and data combined where relevant. Data for outcome 2 and 4 con-
firmed by correspondence with author (from the previous version of this review). Not
able to include outcome 1 (IPD) as data not able to be extracted from figure 6 with
certainty
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Unclear risk Not described
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
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Austrian 1976a (Continued)
Selective reporting (reporting bias) Unclear risk Not described
Austrian 1980a
Methods RCT
Participants Adult inpatients, Dorothea Dix Mental Hospital, USA
Interventions 6-valent PPV (n = 607), or saline placebo (n = 693)
Outcomes A2. Pneumonia (all causes)
A3. Mortality (all causes)
A9. Mortality due to pneumonia
Notes Follow-up continued for 3 years (average 2.2 years)
Participants randomly assigned ’in double-blind fashion’, method not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Method not described
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The trial was conducted in a double-blind fashion”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
High risk Participant withdrawals not described. Discrepancies in out-
comes reported, e.g. deaths
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
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Austrian 1980b
Methods RCT
Participants Adults, Kaiser Permanente Health Plan, USA
Interventions 12-valent PPV (n = 6782) or saline placebo (n = 6818)
Outcomes A1. IPD
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
A6. Definitive pneumococcal pneumonia (vaccine-type)
A9. Mortality due to pneumonia
Notes Average follow-up 2.5 years
Participants randomly allocated by colour codes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Participants randomly assigned by colour codes
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Contents of vials not known to person administering injection,
nor to participants”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participant withdrawals not described
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Benin 2003
Methods Matched case-control study
Participants Navajo adults with IPD aged 18 and over with medical risk factor or above 65 years
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Benin 2003 (Continued)
Interventions 108 IPD case patients recruited in 1996 or 1997
330 control patients without prior IPD or pneumonia
23-valent PPV
Outcomes B1. IPD
B2. Vaccine-type IPD
Notes Matched 1: up to 7 according to age, sex, chronic medical condition (duration, number
of conditions and severity)
Cases more likely to have underlying disease and multiple underlying disease conditions
(P = 0.0002). Cases may have had prior IPD and controls excluded if prior IPD or
pneumonia in previous 10 years
Likely bias against vaccine effectiveness
AIDS patients not excluded
Vaccinated defined as receiving any prior dose (23-valent PPV)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) Low risk Study investigators determining participant inclusion un-
likely to be aware of vaccination status
Confounding
All outcomes
Low risk 4/5 important confounding factors. Study did not control
for smoking due to low prevalence
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk NA
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Due to the specificity of outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear whether there were withdrawals
Selective reporting (reporting bias) Low risk Limited extent to which analysis could have been manip-
ulated to bias the findings
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Davis 1987
Methods Double-blind RCT
Participants Adults with chronic obstructive pulmonary disease, recruited from chest clinics in New
York, USA
Participants excluded if malignant neoplasms, sickle cell disease, severe renal failure,
hepatic impairment
Interventions 14-valent PPV (n = 50) administered subcutaneously (2 brands used), or saline placebo
(n = 53)
Outcomes A1. IPD
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
A7. Presumptive pneumococcal pneumonia
A9. Mortality due to pneumonia
A10. Mortality due to pneumococcal infection
Notes Average follow-up 32 months
Groups appear similar apart fromhigher proportionof vaccinees currently smoking (53%
compared to 33%). More placebo participants had prior pneumonia and pneumococcal
pneumonia (14 and 8 compared to 10 and 5)
Random allocation by table of random numbers
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Unclear risk Method not described
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Staff and participants blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were not aware of study participant group
allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No evidence of selective outcome reporting
Selective reporting (reporting bias) Unclear risk No reason to suspect other bias
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Dominguez 2005
Methods Retrospective, matched case-control study
Participants Cases hospitalised with IPD aged >= 65 years, conducted in Spain
Controls: 2 hospital, 1 outpatient control per case
Interventions 149 cases, 447 controls
23-valent PPV
Outcomes B1. IPD (immunocompetent and immunocompetent elderly)
Notes Matched 3:1 according to age, date of hospitalisation, medical condition and most
important risk factor. The outpatient control was also matched by risk conditional profile
of case
33 case patients (18%) and 59 control patients were excluded as vaccination status could
not be determined
Cases were more likely to have longer mean hospital length of stay and death during
hospitalisation
Considered vaccinated (23-valent PPV) from 14 days following administration
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) Low risk Study investigators determining partici-
pant inclusion unlikely to be aware of vac-
cination status
Confounding
All outcomes
Low risk 3/6 important confounding factors
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk NA
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Due to specificity of outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear whether there were withdrawals
Selective reporting (reporting bias) Low risk Limited extent towhich analysis could have
been manipulated to bias the findings
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Furomoto 2008
Methods Randomised, open-label controlled study
Participants Patients with stable chronic lung disease recruited from respiratory clinic
Interventions 23-valent PPV and influenza vaccine (n = 87), or influenza vaccine alone (n = 80)
Outcomes A2. Pneumonia (all causes)
A3. Mortality (all causes)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Low risk Sealed envelopes
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants probably and clinical assessors
definitely knew allocation to pneumococcal
vaccination, or not, during the study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors aware of participant
study group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Those lost to follow-up or early termination
of follow-up reported but reasons unclear
beyond participant choice
Selective reporting (reporting bias) Unclear risk No evidence of selective outcome reporting
Gaillat 1985
Methods RCT
Participants Older adults living in hospices and retirement homes in France aged between 55 and 85
years
Participants excluded if considered very high risk (> 85 years with major visceral defect/
or 2 minor, bedridden or immunocompromised)
Interventions 14-valent PPV (n = 937) administered subcutaneously, or influenza vaccine (n = 749)
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Gaillat 1985 (Continued)
Outcomes A1. IPD
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
Notes Followed up for 2 years
Case notification to researchers by pre-paid cards then researcher conducted follow-up
visits
Randomised by residential home according to proportion of high-risk patients in each
facility
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk 141 participants excluded from results “due to insufficiently
strict monitoring over the two years in the six establishments
involved. Doctors participated moderately and irregularly”
Selective reporting (reporting bias) High risk 40 participants not accounted for in results
Jackson 2003
Methods Retrospective cohort study
Participants Cohort of older adults aged 65 years and above, enrolled in a GroupHealth Co-operative
in Washington State
Interventions 47,365 people in cohort - study period March 1998 until February 2001
23-valent PPV
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Jackson 2003 (Continued)
Outcomes B1. IPD (immunocompetent and immunocompetent elderly)
Notes Followed up until death, disenrollment fromHMO or end of study (maximum 3 years)
Model adjusted for age, sex, nursing home residence, influenza vaccination, smoking,
chronic illness, previous hospitalisation for pneumonia in last 12 months, number of
outpatient visits. Follow-up until death, disenrolled fromHMOor end of study (3 years)
Considered vaccinated from 14 days following administration
Confirmation IPD confirmed by sterile site culture by personal communication with
author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-random study
Allocation concealment (selection bias) Low risk Study investigators determining participant inclusion un-
likely to be aware of vaccination status
Confounding
All outcomes
Low risk All important confounding factors considered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk NA
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Due to specificity of outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk Limited extent to which analysis could have been manip-
ulated to bias the findings
Kaufman 1947
Methods RCT
Participants Patients of New York City Home, USA, aged above 40 years
Interventions 2-valent PPV given from 1937 to 1938 and 3-valent PPV given later types 1939 to 1942
(n = 5750), or no intervention (n = 5153)
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Kaufman 1947 (Continued)
Outcomes A1. IPD
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A4. IPD (vaccine-type)
A5. Definitive pneumococcal pneumonia
A6. Definitive pneumococcal pneumonia (vaccine-type)
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine-type)
A9. Mortality due to pneumonia
Notes A continuation of Kaufman 1947
Details regarding patient histories were taken but not reported in paper (age comparison
between groups “was about the same, except that there were somewhat more persons in
the oldest and somewhat less persons in the youngest group among the controls”). Non-
pneumonia mortality was 91/1000 in the vaccination group and 89/1000 in the control
group
Average follow-up for each group unclear (pneumonia incidence presented over 6-year
period)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Confounding
All outcomes
Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described. However, likely to be high risk (“5,153 kept as
controls”) and no placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Unclear risk Not described
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Kawakami 2010
Methods Open-label RCT
Participants Participants were diagnosed with chronic respiratory or cardiac illness/hypertension re-
ceiving long-term care from a physician
Interventions 23-valent PPV and influenza vaccine (n = 394), or influenza vaccine alone (n = 392)
Outcomes A2. Pneumonia (all causes)
A3. Mortality (all causes)
A9. Mortality due to pneumonia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Low risk Sealed envelope
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants probably (due to receipt of 1 or 2 vaccines) and clin-
ical assessors definitely knew allocation to pneumococcal vacci-
nation, or not
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Pneumonia was diagnosed by the participant’s physician (not
study personnel)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Those lost to follow-up reported and numbers low (1% of par-
ticipants)
Selective reporting (reporting bias) Unclear risk No evidence of selective outcome reporting
Klastersky 1986
Methods RCT
Participants Patients with bronchogenic carcinoma prior to receiving radiotherapy/chemotherapy,
aged 42 to 47, Brussels, Belgium
Interventions 17-valent PPV (n = 26) administered subcutaneously, or identically packaged saline
placebo (n = 21)
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Klastersky 1986 (Continued)
Outcomes A1. IPD
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
A7. Presumptive pneumococcal pneumonia
A9. Mortality due to pneumonia
A10. Mortality due to pneumococcal infection
Notes 3 participants lost to follow-up (no details of which group). Length of follow-up unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Low risk “The vaccine was prepared in numbered boxes, prepared accord-
ing to prior randomisation”
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk However, staff and participants likely blinded due to method of
allocation concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of incomplete outcome data, however, 3 partici-
pants lost to follow-up (no details of which group)
Selective reporting (reporting bias) Unclear risk No evidence to suspect selective outcome reporting
Koivula 1997
Methods RCT
Participants Older adults residing in town in eastern Finland, aged 60 years or above
Interventions 14-valent PPV and influenza vaccine (n = 1364), or influenza vaccine alone (n = 1473)
Outcomes A3. Mortality (all causes)
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Koivula 1997 (Continued)
Notes Followed up for 3 years; 1983 to 1985. Randomisation appears to have occurred prior
to consent to participate. Following randomisation, participants with high-risk medical
conditions also received annual influenza vaccination
Unable to include all-cause pneumonia as not all pneumonia radiologically typical (ap-
pears to include radiological uncertain)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by computer
Allocation concealment (selection bias) High risk Although participants not aware of assignment, not possible to
conceal as either 1 or 2 vaccines given
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Described as single-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors did not know group allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No evidence of incomplete outcome data
Selective reporting (reporting bias) Unclear risk No evidence to suspect reporting bias due to selective outcome
reporting
Leech 1987
Methods RCT
Participants Participants aged 40 to 89 years, with chronic obstructive lung disease (with FEV1 < 1.5
L), recruited from outpatient department at Montreal Chest hospital, Canada between
January and June 1981
Interventions 14-valent PPV (n = 92) or saline placebo (n = 97); both groups were given influenza
vaccine at the same time and annually thereafter
Outcomes A1. IPD
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
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Leech 1987 (Continued)
Notes Potential participants stratified by age, FEV and sex, then randomised
Follow-up for 2 years at 6-monthly intervals
23 participants lost to follow-up (which group is unclear)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Staff and participants blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors did not know participant study group allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants lost to follow-up with no rationale provided
Selective reporting (reporting bias) Unclear risk No evidence to suspect selective outcome reporting
Maruyama 2010
Methods RCT
Participants Nursing home residents aged 55 to 106 years
Interventions 23-valent PPV (n = 502) or saline placebo (n = 506)
Outcomes A1. IPD
A2. All-cause pneumonia
A3. Mortality (all causes)
A7. Presumptive pneumococcal pneumonia
A9. Mortality due to pneumonia
Notes The pneumococcal urinary antigen test was used to assist in the diagnosis of presumptive
pneumococcal pneumonia (in addition to documented new infiltrate on chest x-ray).
Study results unable to be included in outcome A10, as unable to differentiate those
diagnoses that did not fit definition of confirmed pneumococcal pneumonia
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Maruyama 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation using a random number table
Allocation concealment (selection bias) Low risk Vaccine and placebo were presented in identical single dose sy-
ringe and needle combinations,
labelled with sequential study numbers only
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Staff and participants blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pneumonia was diagnosed by medical staff of respiratory unit of
the affiliated hospital, who were unaware of participant group
allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No evidence of incomplete outcome data
Selective reporting (reporting bias) Unclear risk No evidence of selective outcome reporting
Ortqvist 1998
Methods Double-blind RCT
Participants Non-immunocompromised adults aged 50 to 85 years who had been inpatients for CAP
in Sweden. Potential participants excluded if assumed poor compliance, previous receipt
of PPV, allergy to PPV or immunocompromised
Interventions 23-valent PPV (n = 339) administered intramuscularly (subcutaneous for patients on
anticoagulant therapy), or saline placebo (352)
Outcomes A1. IPD
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A4. IPD (vaccine-type)
A5. Definitive pneumococcal pneumonia
A6. Definitive pneumococcal pneumonia (vaccine-type)
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine-type)
A9. Mortality due to pneumonia
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Ortqvist 1998 (Continued)
Notes Average follow-up 2.5 years
Case ascertainment: participant to contact doctor if temperature above 38 C or cause to
suspect pneumonia recurrence. 1 participant withdrawn (n = 2, as randomised twice)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Specific method not described, however, text states: “randomi-
sation was done by the vaccine manufacturer and the code was
not disclosed until follow-up had ended”
Allocation concealment (selection bias) Low risk Vaccine and placebo were marked with random numbers
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Staff and participants blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors did not know participant study group allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No evidence of incomplete outcome data
Selective reporting (reporting bias) Unclear risk No evidence of selective outcome reporting
Riley 1977
Methods Double-blind RCT
Participants Adults from Tari in Papua New Guinea Highlands
Interventions 14-valent PPV (n=5946), or saline placebo (6012). Surveillance subset of 2713 vaccinees,
2660 controls for disease outcomes
Outcomes A1. IPD
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A4. IPD (vaccine-type)
A5. Definitive pneumococcal pneumonia
A6. Definitive pneumococcal pneumonia (vaccine-type)
Notes Follow-up 3 years for mortality and 16 months morbidity
540 records lost during transport, unclear which group, report likely equal numbers
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Riley 1977 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The vials of vaccine and placebo were then randomly assigned
consecutive numbers
Allocation concealment (selection bias) Low risk Distinguishing labels were removed from the vaccine and
placebo vials
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study was double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) High risk “Records were lost of 540 participants known to have received
an injection”
Shapiro 1984
Methods Matched case-control study
Participants Adults aged 18 years and above with indication for vaccination or above 65 years (n =
180)
Interventions Cases (n = 90) hospitalised with IPD from 1978 to 1982 (no previous pneumococcal
disease)
Controls (n = 90) selected from roster of hospitalised patients with no previous episode
of pneumonia
14-valent PPV
Outcomes B1. IPD (immunocompetent and immunocompetent elderly)
Notes Matched 1:1 according to age, date of hospitalisation, condition identified and vaccina-
tion indication (duration, severity and number of illnesses)
Vaccination history reviewed from 1978 onwards
Vaccinated defined as receiving dose at least 2 weeks prior to selected hospitalisation (14-
valent PPV)
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Shapiro 1984 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-random study
Allocation concealment (selection bias) Low risk Study investigators determining participant inclusion un-
likely to be aware of vaccination status
Confounding
All outcomes
Low risk 2/6 important confounding factors considered, however
critical factors covered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk NA
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Due to specificity of the outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk Limited extent to which analysis could have been manip-
ulated to bias the findings
Shapiro 1991
Methods Matched case-control study
Participants Adults aged 18 years and above with indication for vaccination or above 65 years (n =
2108)
Interventions Cases (n = 1054) hospitalised with IPD from 1984 to 1990 (no previous pneumococcal
disease) and pneumococcal isolate serotyped
Controls (n = 1054) selected from roster of hospitalised patients with no previous episode
of IPD during the study period
Both 14-valent and 23-valent PPV
Outcomes B1. IPD (immunocompetent)
B2. Vaccine-type IPD (immunocompetent and immunocompetent elderly)
Notes Matched 1:1 according to age, date and site of hospitalisation, condition of vaccination
indication (duration, severity and number of illnesses)
Less cases were white (862/921) and had a private physician (829/903). More cases were
residents and chronic care facility (181/117) and died during hospitalisation. Likely bias
against vaccine effectiveness
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Shapiro 1991 (Continued)
Analysis according to indirect cohort method was conducted in a subgroup analysis of
cases with a serotype contained in the 14 valent vaccine compared to non-23 valent or
14 valent serotypes (23 valent non-14 valent serotype cases excluded)
Vaccinated defined as receiving dose at least 2 weeks prior to selected hospitalisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-random study
Allocation concealment (selection bias) Low risk Study investigators determining participant inclusion un-
likely to be aware of vaccination status
Confounding
All outcomes
Low risk 2/6 important confounding factors considered, however
critical factors covered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk NA
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Due to specificity of outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk Limited extent to which analysis could have been manip-
ulated to bias the findings
Simberkoff 1986
Methods Double-blind RCT
Participants High-risk ambulatory patients 55 years and above, referred from clinics, in the USA
(with chronic renal, hepatic, cardiac or pulmonary disease, alcoholism or diabetes)
Excluded if previous receipt of PPV,multiple myeloma, lymphoma or malignant disease,
immunosuppressive treatment, history of splenectomy or functional asplenia
Interventions 14-valent PPV (n = 1175) administered subcutaneously, or saline placebo (1179)
Outcomes A1. IPD
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A4. IPD (vaccine-type)
A5. Definitive pneumococcal pneumonia
A7. Presumptive pneumococcal pneumonia
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Simberkoff 1986 (Continued)
A8. Presumptive pneumococcal pneumonia (vaccine-type)
A9. Mortality due to pneumonia
A10. Mortality due to pneumococcal infection
Notes Mean follow-up period 2.9 years
More vaccinees had prior pneumococcal disease compared to placebo recipients (48 and
30 respectively, P = 0.035)
Additional low-risk patients (n = 59) included for antibody response only
Loss to follow-up not reported (statement in text satisfactory)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Staff and participants blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors did not know participant study group allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No evidence of incomplete outcome data
Selective reporting (reporting bias) Unclear risk No evidence of selective outcome reporting
Sims 1988
Methods Matched case-control
Participants Immunocompetent older adults aged 55 years and above
Interventions Cases (n = 122) IPD cases from Jan 1980 to July 1986
Controls (n = 244) consecutive hospital admissions
Vaccine valency not specified
Outcomes B1. IPD (immunocompetent and immunocompetent elderly)
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Sims 1988 (Continued)
Notes Matched 2:1 according to hospital, admission date, comorbid conditions (number and
severity)
Sample size based on vaccine efficacy at 50%, power 0.80, error 0.05 (one tailed) and
20% vaccination coverage in controls requires 164 cases and 328 controls
Controls excluded if they had radiographically proven pneumonia during the study
period
Vaccinated definition (time since dose) not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-random study
Allocation concealment (selection bias) Low risk Study investigators determining participant inclusion unlikely
to be aware of vaccination status
Confounding
All outcomes
Low risk 3/6 important confounding factors covered, however, critical
factors covered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk NA
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Due to the specificity of outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk Limited extent to which analysis could have been manipulated
to bias the findings
Smit 1977a
Methods RCT
Participants Young adult gold miners in South Africa (recruited within 1 day of arrival)
Interventions 6-valent PPV (n = 983), or meningococcal group A vaccine (n = 1051), or saline (n =
985). Total control n = 2036
Outcomes A2. Pneumonia (all causes)
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine-type)
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Smit 1977a (Continued)
Notes Mean length of follow-up not stated
Recruited between February 1973 to June 1974, with follow-up until May 1975
Maximum duration of follow-up 2.3 years
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not specified
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical observations were made blindly without knowledge
of whether the subject had received pneumococcal vaccine or
control material”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Unclear risk Not described
Smit 1977b
Methods RCT
Participants Young adult gold miners in South Africa (recruited within 1 day of arrival)
Interventions 12-valent PPV (n = 540), or meningococcal types A and C vaccine (n = 585); saline (n
= 550). Total control = 1135
Outcomes A2. Pneumonia (all causes)
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine-type)
Notes Mean length of follow-up not stated
Recruited between July 1974 to January 1976, with follow-up until February 1976
Maximum duration of follow-up 1.6 years
Risk of bias
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Smit 1977b (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Confounding
All outcomes
Unclear risk NA
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical observations were made blindly without knowledge
of whether the subject had received pneumococcal vaccine or
control material”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Unclear risk Not described
Vila-Corcoles 2006
Methods Prospective cohort study
Participants Community-dwelling older adults aged 65 years and above, assigned to primary health-
care centres
Interventions 11,241 members of the cohort. Study period from January 2002 until April 2005
23-valent PPV
Outcomes B1. IPD (immunocompetent and immunocompetent elderly)
B2. Vaccine-type IPD (immunocompetent and immunocompetent elderly)
Notes Cohort observed until study completion or first occurrence of each outcome (maximum
3 years, 4 months)
IPD incidence of study participants 0.64/1000 person-years
Model adjusted for age, sex, number of outpatient visits, history of hospitalisation for
pneumonia in previous 24 months, influenza vaccination status, underlying medical
conditions, current smoking status and immunocompromised status. Vaccination was a
time variable factor; considered vaccinated from 14 days following administration
Results for IPD by vaccine-type only serotypes provided by personal communication
with first author
Risk of bias
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Vila-Corcoles 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-random study
Allocation concealment (selection bias) Low risk Investigators reviewing clinical data unaware of vaccination
status
Confounding
All outcomes
Low risk 6/6 important confounding factors considered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk NA
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Due to specificity of outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk Limited extent to which analysis could have been manipu-
lated to bias the findings
CAP: community-acquired pneumonia
FEV: forced expiratory volume
FEV1: forced expiratory volume in first second
HMO: health maintenance organisation
IPD: invasive pneumococcal disease
NA: not applicable
PPV: pneumococcal polysaccharide vaccine
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ammann 1977 Outcome was changes in antibody titres
Ansaldi 2005 Observational study with non-IPD outcome
Austrian 1976b No useable data due to inadequate reporting
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(Continued)
Bentley 1981 Cohort study, results not controlled for confounding factors
Blay 2007 Observational study with non-IPD outcome
Bolan 1986 Data are included in a subsequent report: Butler 1993
Brieman 2000 HIV-positive participants
Broome 1980 Data are included in a subsequent report: Butler 1993
Butler 1993 Indirect cohort study (no control of confounding factors)
Chang 2012 Observational study with non-IPD outcome
Chiba 2004 All outcomes defined by ICD codes
Chintu 1983 Non-randomised clinical trial, case series only
Christensen 2001 Only early interim results are available
Christenson 2004 Cases of IPD identified by ICD codes. No adjustment for confounding factors
Christenson 2008 Observational study with non-IPD outcome
Douglas 1984 Trial measures efficacy of vaccine in children
Douglas 1986 Trial measures efficacy of vaccine in children
Dworkin 2001 Cohort study in HIV positive participants
Farr 1995 Age of participants from 2 years. No subgroup analysis for adults able to be included
Fletcher 1997 Outcome was changes in antibody titres
Forrester 1987 This study was designed as a case-control study but VE estimate given according to indirect cohort
method, therefore no control of confounding factors in this methodology
Franzen 2000 Observational study with non-IPD outcome
Gilbertson 2011 Observational study with non-IPD outcome
Hedlund 2003 Interim results of Christenson 2004. Methodological issues of case identification by ICD codes and no
control for confounding factors
Honkanen 1999 Could not able be included with RCTs as this trial is not randomised (initially year of birth allocation
but participants also able to choose group). Could not be included in observational review due to lack
of control of confounding factors
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(Continued)
Karma 1985 Trial measures efficacy of vaccine in children
Kaufman 1941 All results included in second report (Kaufman 1947)
Lamontagne 2008 Observational study with non-IPD outcome
Lindenburg 2001 Observational study with non-IPD outcome
MacLeod 1945 No usable data due to inadequate reporting
Manzur 2011 Observational study with non-IPD outcome
MMWR 2001 Not all cases confirmed as IPD (7 of 9 confirmed by blood culture)
Mykietiuk 2006 Case series, no comparison group
Nichol 1999 Cohort study, primary outcome pneumonia defined by ICD codes
Ochoa-Gondar 2008 Observational study with non-IPD outcome. Results for bacteraemic pneumococcal pneumonia were
presented but all participants were involved in the general cohort of the EVAN-65 Study (included study
Vila-Corcoles 2006). Clarified by personal communication with the author
Rodriguez-Barradas 2008 Observational study with non-IPD outcome
Rosen 1983 Trial measures efficacy of vaccine in children
Schembri 2009 Observational study with non-IPD outcome
Skull 2007 Observational study with non-IPD outcome
Steentoft 2007 Unable to separate the role of steroids within this study; comparison of vaccination + steroids versus no
vaccination and most likely a mix of +/- steroids during the 3 months prior to vaccination (49 COPD
patients of whom 13 had no systemic steroids during the preceding 3 months). Unable to contact author
to clarify
Sumitani 2008 Observational study with non-IPD outcome
Teramoto 2007 Study only available in abstract form. Unable to ascertain full methodology details or conduct quality
assessment
Vila-Corcoles 2009 Participants were involved in the general cohort of the EVAN-65 Study (included study Vila-Corcoles
2006). Clarified by personal communication with the author
Vila-Corcoles 2010 IPD cases were identified on the basis of ICD-9 discharge codes
Wagner 2003 Observational study with non-IPD outcome
52Vaccines for preventing pneumococcal infection in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Ya Tseimakh 2006 Study only available in abstract form. Unable to ascertain full methodology details or conduct quality
assessment
COPD: chronic obstructive pulmonary disease
ICD: international classification of diseases
IPD: invasive pneumococcal disease
VE: vaccine effectiveness
Characteristics of ongoing studies [ordered by study ID]
Ryan 2001
Trial name or title Ryan 2001
Methods Double-blind RCT
Participants Over 191,000 military recruits
Interventions 23vPPV compared to placebo
Outcomes All-cause pneumonia, acute respiratory illness, hospitalisation and outpatient encounters
Starting date October 2000
Contact information
Notes
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. RCTs of vaccination versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Invasive pneumococcal disease 11 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 All studies 11 36489 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.14, 0.45]
1.2 i) Adults in low-income
countries
1 5373 Odds Ratio (M-H, Random, 95% CI) 0.14 [0.03, 0.61]
1.3 ii) Adults in high-income
countries with chronic illness
5 3230 Odds Ratio (M-H, Random, 95% CI) 1.56 [0.35, 6.94]
1.4 iii) Adults in high-income
countries
5 27886 Odds Ratio (M-H, Random, 95% CI) 0.20 [0.10, 0.39]
2 Pneumonia, all causes 16 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 All studies 16 47734 Odds Ratio (M-H, Random, 95% CI) 0.72 [0.56, 0.93]
2.2 i) Adults in low-income
countries
4 14562 Odds Ratio (M-H, Random, 95% CI) 0.54 [0.43, 0.67]
2.3 ii) Adults in high-income
countries with chronic illness
6 4010 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.73, 1.19]
2.4 iii) Adults in high-income
countries
6 29186 Odds Ratio (M-H, Random, 95% CI) 0.71 [0.45, 1.12]
3 Mortality, all causes 14 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 All studies 14 47560 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.74, 1.09]
3.2 i) Adults in low-income
countries
1 11958 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.62, 0.99]
3.3 ii) Adults in high-income
countries with chronic illness
6 3603 Odds Ratio (M-H, Random, 95% CI) 1.13 [0.90, 1.43]
3.4 iii) Older adults in
high-income countries
7 32023 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.67, 1.17]
4 Invasive pneumococcal disease
(vaccine types only)
5 31223 Odds Ratio (M-H, Random, 95% CI) 0.18 [0.10, 0.31]
5 Definitive pneumococcal
pneumonia
10 35483 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.15, 0.46]
5.1 All studies 10 35483 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.15, 0.46]
6 Definitive pneumococcal
pneumonia (vaccine types only)
4 30561 Odds Ratio (M-H, Random, 95% CI) 0.13 [0.05, 0.38]
7 Presumptive pneumococcal
pneumonia
9 20335 Odds Ratio (M-H, Random, 95% CI) 0.46 [0.25, 0.84]
8 Presumptive pneumococcal
pneumonia (vaccine types only)
5 18568 Odds Ratio (M-H, Random, 95% CI) 0.27 [0.08, 0.87]
9 Mortality due to pneumonia 9 30723 Odds Ratio (M-H, Random, 95% CI) 0.71 [0.44, 1.16]
10 Mortality due to pneumococcal
infection
3 2445 Odds Ratio (M-H, Random, 95% CI) 2.51 [0.45, 14.13]
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Comparison 2. Non-randomised studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Invasive pneumococcal disease
(all types)
7 OR (Random, 95% CI) Subtotals only
1.1 All studies 7 OR (Random, 95% CI) 0.48 [0.37, 0.61]
1.2 Immunocompetent 6 OR (Random, 95% CI) 0.41 [0.32, 0.52]
1.3 Immunocompetent older
adults
5 OR (Random, 95% CI) 0.32 [0.22, 0.47]
1.4 Cohort studies 2 OR (Random, 95% CI) 0.57 [0.36, 0.89]
1.5 Case-control studies 4 OR (Random, 95% CI) 0.47 [0.32, 0.68]
2 Invasive pneumococcal disease
(vaccine type)
3 OR (Random, 95% CI) Subtotals only
2.1 All studies 3 OR (Random, 95% CI) 0.45 [0.38, 0.54]
2.2 Immunocompetent 2 OR (Random, 95% CI) 0.40 [0.29, 0.54]
2.3 Immunocompetent older
adults
1 OR (Random, 95% CI) 0.66 [0.14, 3.03]
Analysis 1.1. Comparison 1 RCTs of vaccination versus placebo, Outcome 1 Invasive pneumococcal disease.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 1 Invasive pneumococcal disease
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Alfageme 2006 0/298 0/298 Not estimable
Austrian 1980b 0/6782 4/6818 3.7 % 0.11 [ 0.01, 2.07 ]
Davis 1987 1/50 0/53 3.1 % 3.24 [ 0.13, 81.47 ]
Gaillat 1985 0/937 1/749 3.1 % 0.27 [ 0.01, 6.54 ]
Kaufman 1947 8/5750 34/5153 53.8 % 0.21 [ 0.10, 0.45 ]
Klastersky 1986 1/26 1/21 4.0 % 0.80 [ 0.05, 13.60 ]
Leech 1987 1/92 0/97 3.1 % 3.20 [ 0.13, 79.47 ]
Maruyama 2010 0/502 3/504 3.6 % 0.14 [ 0.01, 2.77 ]
0.01 0.1 1 10 100
Favours vaccine Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ortqvist 1998 1/339 5/352 6.9 % 0.21 [ 0.02, 1.77 ]
Riley 1977 2/2713 14/2660 14.5 % 0.14 [ 0.03, 0.61 ]
Simberkoff 1986 1/1145 1/1150 4.2 % 1.00 [ 0.06, 16.08 ]
Subtotal (95% CI) 18634 17855 100.0 % 0.26 [ 0.14, 0.45 ]
Total events: 15 (Vaccine), 63 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.72, df = 9 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 4.74 (P < 0.00001)
2 i) Adults in low-income countries
Riley 1977 2/2713 14/2660 100.0 % 0.14 [ 0.03, 0.61 ]
Subtotal (95% CI) 2713 2660 100.0 % 0.14 [ 0.03, 0.61 ]
Total events: 2 (Vaccine), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0092)
3 ii) Adults in high-income countries with chronic illness
Alfageme 2006 0/298 0/298 Not estimable
Davis 1987 1/50 0/53 21.5 % 3.24 [ 0.13, 81.47 ]
Klastersky 1986 1/26 1/21 27.8 % 0.80 [ 0.05, 13.60 ]
Leech 1987 1/92 0/97 21.6 % 3.20 [ 0.13, 79.47 ]
Simberkoff 1986 1/1145 1/1150 29.0 % 1.00 [ 0.06, 16.08 ]
Subtotal (95% CI) 1611 1619 100.0 % 1.56 [ 0.35, 6.94 ]
Total events: 4 (Vaccine), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
4 iii) Adults in high-income countries
Austrian 1980b 0/6782 4/6818 5.3 % 0.11 [ 0.01, 2.07 ]
Gaillat 1985 0/937 1/749 4.4 % 0.27 [ 0.01, 6.54 ]
Kaufman 1947 8/5750 34/5153 75.6 % 0.21 [ 0.10, 0.45 ]
Maruyama 2010 0/502 3/504 5.1 % 0.14 [ 0.01, 2.77 ]
Ortqvist 1998 1/339 5/352 9.7 % 0.21 [ 0.02, 1.77 ]
Subtotal (95% CI) 14310 13576 100.0 % 0.20 [ 0.10, 0.39 ]
Total events: 9 (Vaccine), 47 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 4 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.70 (P < 0.00001)
0.01 0.1 1 10 100
Favours vaccine Favours control
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Analysis 1.2. Comparison 1 RCTs of vaccination versus placebo, Outcome 2 Pneumonia, all causes.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 2 Pneumonia, all causes
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Alfageme 2006 37/298 39/298 6.8 % 0.94 [ 0.58, 1.52 ]
Austrian 1976a 85/1493 359/3002 8.2 % 0.44 [ 0.35, 0.57 ]
Austrian 1980a 154/607 144/693 8.2 % 1.30 [ 1.00, 1.68 ]
Austrian 1980b 268/6782 274/6818 8.6 % 0.98 [ 0.83, 1.17 ]
Davis 1987 3/50 7/53 2.4 % 0.42 [ 0.10, 1.72 ]
Furomoto 2008 13/87 12/80 4.5 % 1.00 [ 0.43, 2.33 ]
Gaillat 1985 3/937 12/749 2.8 % 0.20 [ 0.06, 0.70 ]
Kaufman 1947 99/5750 227/5153 8.3 % 0.38 [ 0.30, 0.48 ]
Kawakami 2010 67/391 81/387 7.6 % 0.78 [ 0.55, 1.12 ]
Klastersky 1986 2/26 4/21 1.6 % 0.35 [ 0.06, 2.16 ]
Maruyama 2010 63/502 104/504 7.7 % 0.55 [ 0.39, 0.78 ]
Ortqvist 1998 63/339 57/352 7.3 % 1.18 [ 0.80, 1.75 ]
Riley 1977 27/2713 40/2660 6.7 % 0.66 [ 0.40, 1.08 ]
Simberkoff 1986 48/1145 38/1150 7.1 % 1.28 [ 0.83, 1.98 ]
Smit 1977a 37/983 121/2036 7.5 % 0.62 [ 0.42, 0.90 ]
Smit 1977b 9/540 28/1135 5.0 % 0.67 [ 0.31, 1.43 ]
Subtotal (95% CI) 22643 25091 100.0 % 0.72 [ 0.56, 0.93 ]
Total events: 978 (Vaccine), 1547 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 97.58, df = 15 (P<0.00001); I2 =85%
Test for overall effect: Z = 2.56 (P = 0.010)
2 i) Adults in low-income countries
Austrian 1976a 85/1493 359/3002 48.2 % 0.44 [ 0.35, 0.57 ]
Riley 1977 27/2713 40/2660 17.2 % 0.66 [ 0.40, 1.08 ]
Smit 1977a 37/983 121/2036 26.6 % 0.62 [ 0.42, 0.90 ]
Smit 1977b 9/540 28/1135 7.9 % 0.67 [ 0.31, 1.43 ]
Subtotal (95% CI) 5729 8833 100.0 % 0.54 [ 0.43, 0.67 ]
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(. . . Continued)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 158 (Vaccine), 548 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.72, df = 3 (P = 0.29); I2 =19%
Test for overall effect: Z = 5.54 (P < 0.00001)
3 ii) Adults in high-income countries with chronic illness
Alfageme 2006 37/298 39/298 22.8 % 0.94 [ 0.58, 1.52 ]
Davis 1987 3/50 7/53 3.0 % 0.42 [ 0.10, 1.72 ]
Furomoto 2008 13/94 12/97 8.2 % 1.14 [ 0.49, 2.64 ]
Kawakami 2010 67/391 81/387 36.8 % 0.78 [ 0.55, 1.12 ]
Klastersky 1986 2/26 4/21 1.9 % 0.35 [ 0.06, 2.16 ]
Simberkoff 1986 48/1145 38/1150 27.2 % 1.28 [ 0.83, 1.98 ]
Subtotal (95% CI) 2004 2006 100.0 % 0.93 [ 0.73, 1.19 ]
Total events: 170 (Vaccine), 181 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.53, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.57 (P = 0.57)
4 iii) Adults in high-income countries
Austrian 1980a 154/607 144/693 18.7 % 1.30 [ 1.00, 1.68 ]
Austrian 1980b 268/6782 274/6818 19.3 % 0.98 [ 0.83, 1.17 ]
Gaillat 1985 3/937 12/749 7.9 % 0.20 [ 0.06, 0.70 ]
Kaufman 1947 99/5750 227/5153 18.8 % 0.38 [ 0.30, 0.48 ]
Maruyama 2010 63/502 104/504 17.9 % 0.55 [ 0.39, 0.78 ]
Ortqvist 1998 63/339 57/352 17.3 % 1.18 [ 0.80, 1.75 ]
Subtotal (95% CI) 14917 14269 100.0 % 0.71 [ 0.45, 1.12 ]
Total events: 650 (Vaccine), 818 (Control)
Heterogeneity: Tau2 = 0.28; Chi2 = 69.10, df = 5 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 1.3. Comparison 1 RCTs of vaccination versus placebo, Outcome 3 Mortality, all causes.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 3 Mortality, all causes
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Austrian 1980a 35/607 44/693 7.5 % 0.90 [ 0.57, 1.43 ]
Austrian 1980b 45/6782 47/6818 8.2 % 0.96 [ 0.64, 1.45 ]
Davis 1987 14/50 13/53 3.5 % 1.20 [ 0.50, 2.88 ]
Furomoto 2008 7/87 7/80 2.5 % 0.91 [ 0.31, 2.73 ]
Gaillat 1985 232/937 175/749 11.0 % 1.08 [ 0.86, 1.35 ]
Kaufman 1947 40/5750 98/5153 8.8 % 0.36 [ 0.25, 0.52 ]
Kawakami 2010 23/391 25/387 5.9 % 0.91 [ 0.50, 1.62 ]
Klastersky 1986 2/26 4/21 1.1 % 0.35 [ 0.06, 2.16 ]
Koivula 1997 152/1364 166/1473 10.9 % 0.99 [ 0.78, 1.25 ]
Leech 1987 6/92 11/97 2.7 % 0.55 [ 0.19, 1.54 ]
Maruyama 2010 89/502 80/504 9.4 % 1.14 [ 0.82, 1.59 ]
Ortqvist 1998 29/339 28/352 6.4 % 1.08 [ 0.63, 1.86 ]
Riley 1977 133/5946 170/6012 10.9 % 0.79 [ 0.62, 0.99 ]
Simberkoff 1986 211/1145 171/1150 11.1 % 1.29 [ 1.04, 1.61 ]
Subtotal (95% CI) 24018 23542 100.0 % 0.90 [ 0.74, 1.09 ]
Total events: 1018 (Vaccine), 1039 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 41.75, df = 13 (P = 0.00007); I2 =69%
Test for overall effect: Z = 1.04 (P = 0.30)
2 i) Adults in low-income countries
Riley 1977 133/5946 170/6012 100.0 % 0.79 [ 0.62, 0.99 ]
Subtotal (95% CI) 5946 6012 100.0 % 0.79 [ 0.62, 0.99 ]
Total events: 133 (Vaccine), 170 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
3 ii) Adults in high-income countries with chronic illness
Davis 1987 14/50 13/53 6.7 % 1.20 [ 0.50, 2.88 ]
Furomoto 2008 7/94 7/97 4.5 % 1.03 [ 0.35, 3.07 ]
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(. . . Continued)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kawakami 2010 23/391 25/387 14.5 % 0.91 [ 0.50, 1.62 ]
Klastersky 1986 2/26 4/21 1.6 % 0.35 [ 0.06, 2.16 ]
Leech 1987 6/92 11/97 4.9 % 0.55 [ 0.19, 1.54 ]
Simberkoff 1986 211/1145 171/1150 67.7 % 1.29 [ 1.04, 1.61 ]
Subtotal (95% CI) 1798 1805 100.0 % 1.13 [ 0.90, 1.43 ]
Total events: 263 (Vaccine), 231 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.34, df = 5 (P = 0.38); I2 =6%
Test for overall effect: Z = 1.06 (P = 0.29)
4 iii) Older adults in high-income countries
Austrian 1980a 35/607 44/693 12.6 % 0.90 [ 0.57, 1.43 ]
Austrian 1980b 45/6782 47/6818 13.5 % 0.96 [ 0.64, 1.45 ]
Gaillat 1985 232/937 175/749 16.9 % 1.08 [ 0.86, 1.35 ]
Kaufman 1947 40/5750 98/5153 14.2 % 0.36 [ 0.25, 0.52 ]
Koivula 1997 152/1364 166/1473 16.7 % 0.99 [ 0.78, 1.25 ]
Maruyama 2010 89/502 80/504 15.0 % 1.14 [ 0.82, 1.59 ]
Ortqvist 1998 29/339 28/352 11.1 % 1.08 [ 0.63, 1.86 ]
Subtotal (95% CI) 16281 15742 100.0 % 0.88 [ 0.67, 1.17 ]
Total events: 622 (Vaccine), 638 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 28.92, df = 6 (P = 0.00006); I2 =79%
Test for overall effect: Z = 0.86 (P = 0.39)
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Analysis 1.4. Comparison 1 RCTs of vaccination versus placebo, Outcome 4 Invasive pneumococcal disease
(vaccine types only).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 4 Invasive pneumococcal disease (vaccine types only)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Austrian 1976a 10/3943 113/8024 72.1 % 0.18 [ 0.09, 0.34 ]
Kaufman 1947 0/5749 7/5148 3.7 % 0.06 [ 0.00, 1.04 ]
Ortqvist 1998 1/339 5/352 6.5 % 0.21 [ 0.02, 1.77 ]
Riley 1977 2/2713 14/2660 13.8 % 0.14 [ 0.03, 0.61 ]
Simberkoff 1986 1/1145 1/1150 3.9 % 1.00 [ 0.06, 16.08 ]
Total (95% CI) 13889 17334 100.0 % 0.18 [ 0.10, 0.31 ]
Total events: 14 (Vaccine), 140 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.19, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 6.14 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 RCTs of vaccination versus placebo, Outcome 5 Definitive pneumococcal
pneumonia.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 5 Definitive pneumococcal pneumonia
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Alfageme 2006 0/298 0/298 Not estimable
Austrian 1980b 0/6782 4/6818 3.9 % 0.11 [ 0.01, 2.07 ]
Davis 1987 1/50 0/53 3.2 % 3.24 [ 0.13, 81.47 ]
Gaillat 1985 0/937 1/749 3.2 % 0.27 [ 0.01, 6.54 ]
Kaufman 1947 8/5750 34/5153 55.8 % 0.21 [ 0.10, 0.45 ]
Klastersky 1986 1/26 1/21 4.1 % 0.80 [ 0.05, 13.60 ]
Leech 1987 1/92 0/97 3.2 % 3.20 [ 0.13, 79.47 ]
Ortqvist 1998 1/339 5/352 7.2 % 0.21 [ 0.02, 1.77 ]
Riley 1977 2/2713 14/2660 15.1 % 0.14 [ 0.03, 0.61 ]
Simberkoff 1986 1/1145 1/1150 4.3 % 1.00 [ 0.06, 16.08 ]
Total (95% CI) 18132 17351 100.0 % 0.26 [ 0.15, 0.46 ]
Total events: 15 (Vaccine), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.56, df = 8 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.57 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 RCTs of vaccination versus placebo, Outcome 6 Definitive pneumococcal
pneumonia (vaccine types only).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 6 Definitive pneumococcal pneumonia (vaccine types only)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Austrian 1980b 0/6782 4/6818 12.9 % 0.11 [ 0.01, 2.07 ]
Kaufman 1947 0/5749 7/5148 13.4 % 0.06 [ 0.00, 1.04 ]
Ortqvist 1998 1/339 5/352 23.7 % 0.21 [ 0.02, 1.77 ]
Riley 1977 2/2713 14/2660 50.0 % 0.14 [ 0.03, 0.61 ]
Total (95% CI) 15583 14978 100.0 % 0.13 [ 0.05, 0.38 ]
Total events: 3 (Vaccine), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 RCTs of vaccination versus placebo, Outcome 7 Presumptive pneumococcal
pneumonia.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 7 Presumptive pneumococcal pneumonia
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alfageme 2006 0/298 5/298 3.6 % 0.09 [ 0.00, 1.62 ]
Davis 1987 2/50 0/53 3.3 % 5.52 [ 0.26, 117.76 ]
Kaufman 1947 34/5750 96/5153 17.7 % 0.31 [ 0.21, 0.46 ]
Klastersky 1986 2/26 4/21 7.1 % 0.35 [ 0.06, 2.16 ]
Maruyama 2010 14/502 37/504 15.9 % 0.36 [ 0.19, 0.68 ]
Ortqvist 1998 19/339 16/352 15.4 % 1.25 [ 0.63, 2.47 ]
Simberkoff 1986 19/1145 15/1150 15.4 % 1.28 [ 0.65, 2.53 ]
Smit 1977a 9/983 78/2036 15.3 % 0.23 [ 0.12, 0.46 ]
Smit 1977b 1/540 25/1135 6.2 % 0.08 [ 0.01, 0.61 ]
Total (95% CI) 9633 10702 100.0 % 0.46 [ 0.25, 0.84 ]
Total events: 100 (Vaccine), 276 (Control)
Heterogeneity: Tau2 = 0.50; Chi2 = 31.74, df = 8 (P = 0.00010); I2 =75%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 RCTs of vaccination versus placebo, Outcome 8 Presumptive pneumococcal
pneumonia (vaccine types only).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 8 Presumptive pneumococcal pneumonia (vaccine types only)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kaufman 1947 1/5748 20/5140 16.8 % 0.04 [ 0.01, 0.33 ]
Ortqvist 1998 1/339 1/352 11.7 % 1.04 [ 0.06, 16.67 ]
Simberkoff 1986 7/1145 6/1150 25.4 % 1.17 [ 0.39, 3.50 ]
Smit 1977a 9/983 78/2036 29.1 % 0.23 [ 0.12, 0.46 ]
Smit 1977b 1/540 25/1135 16.9 % 0.08 [ 0.01, 0.61 ]
Total (95% CI) 8755 9813 100.0 % 0.27 [ 0.08, 0.87 ]
Total events: 19 (Vaccine), 130 (Control)
Heterogeneity: Tau2 = 1.15; Chi2 = 13.17, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 RCTs of vaccination versus placebo, Outcome 9 Mortality due to pneumonia.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 9 Mortality due to pneumonia
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Austrian 1980a 23/607 30/693 15.2 % 0.87 [ 0.50, 1.52 ]
Austrian 1980b 36/6782 38/6818 16.2 % 0.95 [ 0.60, 1.50 ]
Davis 1987 2/50 4/53 5.6 % 0.51 [ 0.09, 2.92 ]
Kaufman 1947 31/5750 98/5153 16.7 % 0.28 [ 0.19, 0.42 ]
Kawakami 2010 11/391 13/387 12.4 % 0.83 [ 0.37, 1.88 ]
Klastersky 1986 1/26 1/21 2.6 % 0.80 [ 0.05, 13.60 ]
Maruyama 2010 13/502 26/504 13.9 % 0.49 [ 0.25, 0.96 ]
Ortqvist 1998 2/339 3/352 5.3 % 0.69 [ 0.11, 4.16 ]
Simberkoff 1986 16/1145 8/1150 12.0 % 2.02 [ 0.86, 4.75 ]
Total (95% CI) 15592 15131 100.0 % 0.71 [ 0.44, 1.16 ]
Total events: 135 (Vaccine), 221 (Control)
Heterogeneity: Tau2 = 0.33; Chi2 = 28.17, df = 8 (P = 0.00044); I2 =72%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours vaccine Favours control
66Vaccines for preventing pneumococcal infection in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 RCTs of vaccination versus placebo, Outcome 10 Mortality due to
pneumococcal infection.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 10 Mortality due to pneumococcal infection
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Davis 1987 1/50 0/53 28.8 % 3.24 [ 0.13, 81.47 ]
Klastersky 1986 1/26 1/21 37.2 % 0.80 [ 0.05, 13.60 ]
Simberkoff 1986 3/1145 0/1150 34.0 % 7.05 [ 0.36, 136.62 ]
Total (95% CI) 1221 1224 100.0 % 2.51 [ 0.45, 14.13 ]
Total events: 5 (Vaccine), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Non-randomised studies, Outcome 1 Invasive pneumococcal disease (all types).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 2 Non-randomised studies
Outcome: 1 Invasive pneumococcal disease (all types)
Study or subgroup log [OR] OR Weight OR
(SE) IV,Random,95% CI IV,Random,95% CI
1 All studies
Benin 2003 -0.3011 (0.2805) 14.7 % 0.74 [ 0.43, 1.28 ]
Dominguez 2005 -1.2039 (0.2652) 15.8 % 0.30 [ 0.18, 0.50 ]
Jackson 2003 -0.5798 (0.259) 16.3 % 0.56 [ 0.34, 0.93 ]
Shapiro 1984 -1.1086 (0.4752) 6.4 % 0.33 [ 0.13, 0.84 ]
Shapiro 1991 -0.6348 (0.1337) 31.7 % 0.53 [ 0.41, 0.69 ]
Sims 1988 -1.2039 (0.376) 9.4 % 0.30 [ 0.14, 0.63 ]
Vila-Corcoles 2006 -0.5108 (0.5037) 5.8 % 0.60 [ 0.22, 1.61 ]
Subtotal (95% CI) 100.0 % 0.48 [ 0.37, 0.61 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 8.75, df = 6 (P = 0.19); I2 =31%
Test for overall effect: Z = 5.78 (P < 0.00001)
2 Immunocompetent
Dominguez 2005 -1.4271 (0.3517) 10.3 % 0.24 [ 0.12, 0.48 ]
Jackson 2003 -1.0498 (0.4567) 6.5 % 0.35 [ 0.14, 0.86 ]
Shapiro 1984 -1.2039 (0.5994) 3.9 % 0.30 [ 0.09, 0.97 ]
Shapiro 1991 -0.755 (0.0432) 64.6 % 0.47 [ 0.43, 0.51 ]
Sims 1988 -1.2039 (0.376) 9.2 % 0.30 [ 0.14, 0.63 ]
Vila-Corcoles 2006 -0.5108 (0.5037) 5.4 % 0.60 [ 0.22, 1.61 ]
Subtotal (95% CI) 100.0 % 0.41 [ 0.32, 0.52 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.10, df = 5 (P = 0.30); I2 =18%
Test for overall effect: Z = 7.27 (P < 0.00001)
3 Immunocompetent older adults
Dominguez 2005 -1.4271 (0.3517) 30.3 % 0.24 [ 0.12, 0.48 ]
Jackson 2003 -1.0498 (0.4567) 18.0 % 0.35 [ 0.14, 0.86 ]
Shapiro 1984 -1.2039 (0.5994) 10.4 % 0.30 [ 0.09, 0.97 ]
Sims 1988 -1.2039 (0.376) 26.5 % 0.30 [ 0.14, 0.63 ]
Vila-Corcoles 2006 -0.5108 (0.5037) 14.8 % 0.60 [ 0.22, 1.61 ]
Subtotal (95% CI) 100.0 % 0.32 [ 0.22, 0.47 ]
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(. . . Continued)
Study or subgroup log [OR] OR Weight OR
(SE) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 2.31, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 5.90 (P < 0.00001)
4 Cohort studies
Jackson 2003 -0.5798 (0.259) 79.1 % 0.56 [ 0.34, 0.93 ]
Vila-Corcoles 2006 -0.5108 (0.5037) 20.9 % 0.60 [ 0.22, 1.61 ]
Subtotal (95% CI) 100.0 % 0.57 [ 0.36, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
5 Case-control studies
Benin 2003 -0.3011 (0.2805) 23.7 % 0.74 [ 0.43, 1.28 ]
Dominguez 2005 -1.2039 (0.2652) 25.1 % 0.30 [ 0.18, 0.50 ]
Shapiro 1984 -1.1086 (0.4752) 12.2 % 0.33 [ 0.13, 0.84 ]
Shapiro 1991 -0.6348 (0.1337) 39.0 % 0.53 [ 0.41, 0.69 ]
Subtotal (95% CI) 100.0 % 0.47 [ 0.32, 0.68 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 6.61, df = 3 (P = 0.09); I2 =55%
Test for overall effect: Z = 3.94 (P = 0.000082)
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Analysis 2.2. Comparison 2 Non-randomised studies, Outcome 2 Invasive pneumococcal disease (vaccine
type).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 2 Non-randomised studies
Outcome: 2 Invasive pneumococcal disease (vaccine type)
Study or subgroup log [OR] OR Weight OR
(SE) IV,Random,95% CI IV,Random,95% CI
1 All studies
Benin 2003 -0.478 (0.4184) 4.7 % 0.62 [ 0.27, 1.41 ]
Shapiro 1991 -0.8209 (0.0936) 93.9 % 0.44 [ 0.37, 0.53 ]
Vila-Corcoles 2006 -0.4155 (0.7776) 1.4 % 0.66 [ 0.14, 3.03 ]
Subtotal (95% CI) 100.0 % 0.45 [ 0.38, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 8.81 (P < 0.00001)
2 Immunocompetent
Shapiro 1991 -0.9416 (0.1595) 96.0 % 0.39 [ 0.29, 0.53 ]
Vila-Corcoles 2006 -0.4155 (0.7776) 4.0 % 0.66 [ 0.14, 3.03 ]
Subtotal (95% CI) 100.0 % 0.40 [ 0.29, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 5.89 (P < 0.00001)
3 Immunocompetent older adults
Vila-Corcoles 2006 -0.4155 (0.7776) 100.0 % 0.66 [ 0.14, 3.03 ]
Subtotal (95% CI) 100.0 % 0.66 [ 0.14, 3.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
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A D D I T I O N A L T A B L E S
Table 1. Risk of bias for non-randomised studies
Confounder Jackson 2003 Vila-Corcoles
2006
Benin 2003 Dominguez 2005 Shapiro 1991 Shapiro 1984
Age Yes Yes Yes Yes Yes Yes
Sex Yes Yes Yes Yes No No
Chronic Illness Yes Yes Yes Yes Yes Yes
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Table 1. Risk of bias for non-randomised studies (Continued)
Smoking Yes Yes No No No No
Influenza vacci-
nation
Yes Yes Yes No No No
Nursing home
resident
Yes Yes No No No No
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy for randomised trials
MEDLINE (Ovid)
1 Streptococcus pneumoniae/
2 streptococcus pneumoniae.tw.
3 “s. pneumoniae”.tw.
4 exp Pneumococcal Infections/
5 (pneumococcal adj2 (infection* or disease*)).tw.
6 (pneumococc* adj5 (pneumon* or sepsis or sinusit* or meningit* or otitis media)).tw.
7 bacteraemic pneumon*.tw.
8 (invasive pneumococcal disease or ipd).tw.
9 or/1-8
10 exp Vaccines/
11 exp Vaccination/
12 Immunization/
13 immunoprophylaxis.tw.
14 (immuni* or inocul* or vaccin*).tw.
15 or/10-14
16 9 and 15
17 Pneumococcal Vaccines/
18 pneumococcal polysaccharide vaccin*.tw,nm.
19 ppv*.tw,nm.
20 pneumovax*.tw,nm.
21 or/16-20
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Appendix 2. EMBASE (Elsevier) search strategy for randomised trials
20. #15 AND #19
19. #16 OR #17 OR #18
18. ((singl* OR doubl*) NEAR/2 (blind* OR mask*)):ab,ti
17. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross-over’:ab,ti OR ’cross over’:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti
16. ’randomised controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
15. #12 OR #13 OR #14
14. ’pneumococcal polysaccharide vaccine’:ab,ti OR ’pneumococcal polysaccharide vaccines’:ab,ti OR ppv*:ab,ti OR pneumovax*:
ab,ti
13. ’pneumococcus vaccine’/exp
12. #8 AND #11
11. #9 OR #10
10. immuni*:ab,ti OR vaccin*:ab,ti OR inocul*:ab,ti
9. ’vaccine’/exp OR ’vaccination’/de OR ’immunization’/de OR ’immunoprophylaxis’/de
8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
7. ’invasive pneumococcal disease’:ab,ti OR ipd:ab,ti
6. ’bacteraemic pneumonia’:ab,ti
5. (pneumococc* NEAR/5 (pneumon* OR sepsis OR sinusit* OR meningit* OR ’otitis media’)):ab,ti
4. (pneumococcal NEAR/2 (infection* OR disease*)):ab,ti
3. ’pneumococcal infection’/exp
2. ’streptococcus pneumoniae’:ab,ti OR ’s. pneumoniae’:ab,ti
1. ’streptococcus pneumoniae’/de
Appendix 3. MEDLINE (Ovid) search strategy for non-randomised studies
1 Comparative Study/
2 Follow-Up Studies/
3 Time Factors/
4 chang*.tw.
5 evaluat*.tw.
6 reviewed.tw.
7 prospective*.tw.
8 retrospective*.tw.
9 baseline.tw.
10 cohort.tw.
11 case series.tw.
12 case control.tw.
13 (compare* or compara*).tw.
14 or/1-13
15 Pneumococcal Vaccines/
16 pneumococcal polysaccharide vaccin*.tw.
17 (ppv* adj10 (pneumococc* or pneumon*)).tw.
18 pneumovax*.tw.
19 or/15-18
20 14 and 19
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Appendix 4. EMBASE (Elsevier) search strategy for non-randomised studies
#17. #5 AND #16
#16. #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
#15. retrospective:ab,ti
#14. consecutive:ab,ti
#13. baseline:ab,ti
#12. reviewed:ab,ti
#11. evaluat*:ab,ti
#10. chang*:ab,ti
#9. ’clinical trial’/de
#8. ’major clinical study’/de
#7. ’treatment outcome’/de
#6. ’controlled study’/de
#5. #1 OR #2 OR #3 OR #4
#4. pneumovax*:ab,ti AND [embase]/lim 179 23 Jun 2011
#3. (ppv* NEAR/10 (pneumococ* OR pneumon*)):ab,ti
#2. ’pneumococcal polysaccharide vaccine’:ab,ti OR ’pneumococcal polysaccharide vaccines’:ab,ti
#1. ’pneumococcus vaccine’/de
Appendix 5. Details of previous searches
The initial review (Dear 2003) included electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library 2003, Issue 2) which includes the Cochrane Acute Respiratory Infections (ARI) Group Specialised Register;
MEDLINE (January 1966 to June 2003); and EMBASE (1974 to June 2003). Search terms included ’pneumococcal vaccine’ or
’pneumococcal immunisation’ and ’trials’ or ’controlled trials’. Other search terms were not specified.
For this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007,
Issue 2); MEDLINE (January 1966 to June 2007); and EMBASE (1974 to June 2007). The following MEDLINE search terms were
run over CENTRAL and adapted for EMBASE.
MEDLINE (OVID)
1 exp Pneumococcal Vaccines/
2 pneumococcal vaccine$.mp.
3 (pneumococcal adj (immunis$ or immuniz$)).mp.
4 exp Streptococcus pneumoniae/
5 exp Vaccination/
6 (immunis$ or immuniz$ or vaccin$).mp.
7 or/5-6
8 4 and 7
9 or/1-3,8
10 RANDOMISED CONTROLLED TRIAL.pt.
11 CONTROLLED CLINICAL TRIAL.pt.
12 RANDOMISED CONTROLLED TRIALS.sh.
13 RANDOM ALLOCATION.sh.
14 DOUBLE BLIND METHOD.sh.
15 SINGLE-BLIND METHOD.sh.
16 or/10-15
17 Animals/
18 Humans/
19 17 not 18
20 16 not 19
21 CLINICAL TRIAL.pt.
22 exp Clinical Trials/
23 (clin$ adj25 trial$).ti,ab.
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24 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
25 PLACEBOS.sh.
26 placebo$.ti,ab.
27 random$.ti,ab.
28 or/21-27
29 28 not 19
30 20 or 29
31 9 and 30
The following terms were used for reports of non-randomised trials within MEDLINE:
1 exp Pneumococcal Vaccines/
2 pneumococcal vaccine$.mp.
3 (pneumococcal adj (immunis$ or immuniz$)).mp.
4 exp Streptococcus pneumoniae/
5 exp Vaccination/
6 (immunis$ or immuniz$ or vaccin$).mp.
7 or/5-6
8 4 and 7
9 or/1-3,8
10 exp Cohort Studies/
11 exp Case-Control Studies/
12 exp Intervention Studies/
13 exp Prospective Studies/
14 exp Longitudinal Studies/
15 observational stud$.mp
16 uncontrolled stud$.mp.
17 latin square$.mp.
18 factorial.mp.
19 Evaluation Studies.pt.
20 or/10-19
21 9 and 20
F E E D B A C K
Best systematic of 23-valent pneumococcal vaccine
Summary
Dear Authors,
The inclusion of non-controlled studies in the current systematic review is clearly a step forward. The case-control studies enables an
analysis of invasive pneumococcal disease that is not possible to do with the prospective studies that have been performed, due to lack of
power. However, there is also a well performed cohort study, adjusted for background factors, that showed the same preventive efficacy
against IPD (Jackson NEJMMAy 2003). Why was that not included? The search strategy stated that you included papers up to June
2003.
For your information, there are some new data from the study that was published as an early report in Lancet 2001 by Christenson et
al. This, however, was published during the fall of 2003. (Hedlund J, Christenson B, Lundbergh P, Örtqvist Å. Effects of a large-scale
intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a one-year follow-up. Vaccine 2003; 21: 3906-11).
Although we are still working with a “complete” background adjustment of the groups to minimise biases, the results of this paper was
sex and age adjusted. In addition, a comparison was made between influenza season and non-influenza. In that comparison it can be
seen that there was a significant prevention against both influenza, pneumonia and IPD during the influenza season in patients who
had received influenza and/or pneumococcal vaccine. During the non-influenza season, however, there was no difference concerning
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influenza, whereas there was still a significant protection against pneumonia. For IPD the RR was the same as during the influenza
season (0.47) but there was to few cases to make it significant.
Finally, in your conclusions you make a mistake by stating that typical figures of IPD in developed countries is about 10 per 100.000
per year. That may be so for the whole population but in the elderly where this calculation is of interest, the correct figure is about 50
per 100.000 per year, thereby reducing the NNT to about 4000 vaccinations per infection avoided.
With the best wishes,
Ake
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
See reply to comment # 2
Contributors
Ake Ortqvist
Biased assessment of pneumococcal vaccine effect
Summary
The assessment of pneumococcal vaccine in preventing invasive pneumococcal disease (IPD)of this review is biased in favour of the
vaccine and some graphs are misleading.
Take notice that:
No quality assessment has ben made of the observational studies included.
Results of heterogeneous studies are displayed in forest plots (see autoco 06 for instance) where results obtained in young adults are
displayed with results obtained in the elderly. This is not appropriate and is misleading for the not expert.
Assessment of effectiveness of IPV rest on results of Kaufman 1947, no random assignment, no blind researchers, no placebo group,
only three serotypes vaccine (?); Shapiro 1984, results go in favour of the vaccine when data is unmatched(!). Simm 1988, excluded
46% of subjects because of lack of information and did not provide information on pneumococcus serotypes; Shapiro 1991, excluded
121 cases because were originated by one of the 23 serotypes included in the 23 valent vaccine but nevertheless reports a non biased
effectiveness in the elderly of 0,6 (IC95% 0,29 yo 1,23); and Butler 1993, no exposure information on 36% of subjects included, a
rate that would invalidate any observational study.
This could go on but you can go to Puig-Barbera et al to get a much more “Cochrane” description and analysis of the data available.
In our current state of knowledge it cannot be assured that the polysaccharide non-conjugated vaccine is free of deleterious effects
in the elderly. Applying the precautionary principle this possibility should be clearly discarded. Meanwhile influenza vaccine does a
tremendous good job preventing pneumonia in the elderly.
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
We entirely agree that any positive assessment of the vaccine rests on the very old pseudo-randomised trial of Kaufman (1947), and
on the observational studies. However, we do point out the crucial importance of the Kaufman study in the RCT part of our review.
Our analyses are presented both with and without this study for this reason. Indeed our conclusions from this part of the review are
decidedly negative: for example we suggest that a large RCT carried out now would fail to show any benefit. We include a table showing
how the apparent efficacy of the vaccine increases monotonically as one progressively includes the poorer quality, older studies, and
point out that several recent high quality randomised studies consistently showed no effect against all-cause pneumonia. Fedson and
Liss have argued that the failure of other meta-analyses to demonstrate a benefit against this outcome should be seen as an inconclusive
rather than negative result on the grounds that, if 30 to 50% of all pneumonias are pneumococcal, a VE of 50% against pneumococcal
pneumonia equates to a VE of 15 to 25% against all-cause pneumonia.(Fedson, 2004) Our results cannot discount this possibility.
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We note your concern about the inclusion criteria for observational studies but believe a more fundamental issue was the decision to
incorporate observational studies within the review. Our initial review was conducted in accordance with the protocol. That version of
the review reached a largely negative assessment of the efficacy of polysaccharide pneumococcal vaccines in preventing pneumonia and
death. It was felt by the Editors that this would deliver an unbalanced message, since it made no mention of other important medical
endpoints that the RCTs do not address, in particular invasive pneumococcal disease. The review was therefore expanded specifically
in order to include the observational studies and it could be argued that the impact of this decision was to bias the review in favour
of the vaccine. Whether such a process is proper for a Cochrane Systematic Review is perhaps doubtful but we have still attempted to
assess the evidence fairly. We note that Ave Ortqvist has indicated support for this approach in other comments posted on this review.
Dr Puig-Barbera suggests we should read the paper by Puig-Barbera et al to “get a much more ”Cochrane“ description and analysis
of the data available”. The clear implication here is that our results are biased by the manner in which we included and analysed the
non-randomised studies. It is true that we have not included a formal, numerical assessment of quality of the observational studies.
Probably there is no scale for such studies that would serve as well as the Jadad scale does for RCTs. We have noted the criteria used
for assessment of observational studies by Puig-Barbera et al but do not agree that these criteria are any more valid than the approach
used by us. We note with interest that according to the criteria of Puig-Barbera et al, the study by Forrester et al was rated ahead of
a number of other observational studies and was included when others were excluded. In our review, we have described a number of
serious flaws in Forrester et al, not least of which was the failure to conduct a matched analysis on a matched case-control study.
From the paper by Puig-Barbera et al, it appears that the observational studies have been analysed in an unmatched fashion. We believe
this is invalid since, as we have explained in our review, all but one of the observational studies included were matched case-control
studies. For our analysis we combined the estimates of OR based on conditional logistic regression in each study (which accounts for
the matching) and calculated a weighted average log-OR using Stata. Furthermore, it is simplistic to assume that an unmatched analysis
of such studies will always approach the null and that failure to do so represents bias in the study.
We do acknowledge that it might be of value to report the high exclusion rates in the observational studies and are grateful for the
(implied) suggestion. As for the forest plots, they can be stratified in many ways. We suggest that the date of publication is more
important in this regard than the age range of subjects.
We agree with Dr Ortqvist’s suggestion that the NNT should be calculated for the older age group rather than for all adults.
We thank Dr Puig-Barbera and Dr Ortqvist for their comments, and thank the Comments Editor for permitting this response.
Ross Andrews
John Holden
David Tatham
Keith Dear
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Contributors
Joan Puig-Barbera
Reply to comment by Dr Puig-Barbera
Summary
Dear Dr Puig-Barbera,
There are small or big flaws in all studies. The results of the case-control studies included in the Cochrane analysis are corroborated by
the results of the two most recent prospective studies (Honkanen and our own) where there was a clear trend for a 70-80% protection
of the 23-valent vaccine against bacteraemic pneumococcal pneumonia. A similar finding was published in a cohort study, adjusted for
background factors, by Lisa Jackson in NEJM 2003.
Although I agree with you concerning the good effect of influenza vaccine, you’re of course aware of that there is no prospective
controlled study in the elderly showing that influenza vaccine prevents against severe influenza or pneumonia? The only controlled
study showing a protection of the vaccine against clinical (irrespective of severity) and serological influenza.
With the best wishes,
Ake
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I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
See reply to comment #2
Contributors
Ake Ortqvist
WH A T ’ S N E W
Last assessed as up-to-date: 22 June 2012.
Date Event Description
22 June 2012 New citation required but conclusions have not changed Review conclusions have not significantly altered.
22 June 2012 New search has been performed Updated search conducted. We included three new
randomised controlled trials (RCTs) (Furomoto 2008;
Kawakami 2010; Maruyama 2010), excluded three new
RCTs (Steentoft 2007; Teramoto 2007; Ya Tseimakh
2006) and excluded 13 non-RCTs (Blay 2007; Chang
2012; Christenson 2008; Gilbertson 2011; Lamontagne
2008; Manzur 2011; Ochoa-Gondar 2008; Rodriguez-
Barradas 2008; Schembri 2009; Skull 2007; Sumitani
2008; Vila-Corcoles 2009; Vila-Corcoles 2010).
H I S T O R Y
Protocol first published: Issue 2, 1996
Review first published: Issue 4, 2003
Date Event Description
15 July 2010 New search has been performed Searches conducted.
9 June 2008 Amended Converted to new review format.
25 July 2004 Feedback has been incorporated Feedback comment added.
23 June 2003 New search has been performed Searches conducted.
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C O N T R I B U T I O N S O F A U T H O R S
Holden (JH) and Tatham (DT) were involved in the preparation of the initial protocol, the searches for studies and the assessment of
new randomised controlled trials (RCTs) for inclusion in this updated review. JH conducted the updated ’Risk of bias’ assessment for
the RCTs.
Andrews (RA) joined in May 2001 to assist with incorporating non-RCTs in the review. For this update, RA reviewed observational
studies for inclusion in the review, conducted the updated ’Risk of bias’ assessment for observational studies and contributed to writing
this updated review.
Moberley (SM) joined in 2006 to assist with the update of the review, conducted electronic searches, selected observational studies and
re-extracted data for the additional outcomes in the RCTs. For this update, SM reviewed observational and randomised studies for
inclusion in the review, conducted the updated ’Risk of bias’ assessment for observational and randomised studies, conducted the data
analysis and wrote this updated review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Menzies School of Health Research, Australia.
• St. Helens Multidisciplinary Audit Advisory Group, UK.
External sources
• No sources of support supplied
N O T E S
Included studies
We included non-randomised controlled trials (non-RCTs) provided adjustment had been made for important confounding factors.
This essentially excluded studies of vaccine effectiveness utilising the indirect-cohort method.
Methods
We revised the outcomes assessed. Primary outcomes are invasive pneumococcal disease (IPD) (previously, bacteraemic pneumococcal
pneumonia was considered separately), all-cause pneumonia and all-cause mortality.
We conducted subgroup analysis according to prespecified characteristics of trial participants that were considered clinically relevant
and would lead to recommendations for vaccination according to different populations at risk of pneumococcal disease. These included
otherwise healthy adults in low-income countries, adults with chronic illness in high-income countries and otherwise healthy adults in
high-income countries.
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Findings
When considering all invasive pneumococcal disease, this meta-analysis found strong evidence of protective efficacy.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Case-Control Studies; Pneumococcal Vaccines [∗therapeutic use]; Pneumonia, Pneumococcal [∗prevention & control]; Prospective
Studies; Randomized Controlled Trials as Topic
MeSH check words
Adult; Aged; Humans; Middle Aged
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